CN103694236A - Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity - Google Patents

Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity Download PDF

Info

Publication number
CN103694236A
CN103694236A CN201310463448.2A CN201310463448A CN103694236A CN 103694236 A CN103694236 A CN 103694236A CN 201310463448 A CN201310463448 A CN 201310463448A CN 103694236 A CN103694236 A CN 103694236A
Authority
CN
China
Prior art keywords
alkane
group
synthetic
follows
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201310463448.2A
Other languages
Chinese (zh)
Other versions
CN103694236B (en
Inventor
张小虎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou pharmaceutical Limited by Share Ltd
Original Assignee
SUZHOU YUNXUAN PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUZHOU YUNXUAN PHARMACEUTICAL Co Ltd filed Critical SUZHOU YUNXUAN PHARMACEUTICAL Co Ltd
Priority to CN201310463448.2A priority Critical patent/CN103694236B/en
Priority to PCT/US2013/077305 priority patent/WO2014113191A1/en
Priority to US14/761,166 priority patent/US9695178B2/en
Priority to EP13871618.8A priority patent/EP2945623B1/en
Publication of CN103694236A publication Critical patent/CN103694236A/en
Application granted granted Critical
Publication of CN103694236B publication Critical patent/CN103694236B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity, which comprises compound and pharmaceutically acceptable salt thereof, various isotopes, various isomers or various crystal structures, and the product comprises the structure shown in the general formula I: wherein, X is a five-membered or six-membered aromatic ring, heteroaromatic ring and heterocyclic ring, and substituted derivatives thereof. The novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity provided by the invention can block transmembrane protein acceptor SMO, and block hedgehog pathway Hedgehog, thereby inhibiting abnormal growth of cells, blocking migration and regeneration of tumor cells with obvious antineoplastic effect.

Description

A kind of pyrimidine skeleton has the new antitumoral compounds of hedgehog path antagonistic activity
Technical field
The present invention relates to medical technical field, relate in particular to the new antitumoral compounds that a kind of pyrimidine skeleton has hedgehog path antagonistic activity.
Background technology
Malignant tumour is one of main disease of harm humans health, the annual malignant tumour new cases approximately 1,090 ten thousand in the whole world, and every year because of the dead patient approximately 6,700,000 [1] of malignant tumour, therefore, the key subjects of control Yi Shi the world of medicine of tumour, wherein the research and development of antitumor drug are explored huge variation have been occurred through years of researches; With antitumor drug conventional on preclinical therapy, be mainly cytotoxic drug, this class antitumour drug has poor selectivity, toxic side effect and by force, easily produces the shortcomings such as resistance; In recent years along with the progress at full speed of life science, progressively being illustrated of the various primary processes such as interaction of the signal transduction in malignant cell, the regulation and control of cell cycle, apoptotic induction, vasculogenesis and cell and extracellular matrix, using the key enzyme of some intracellular signal transduction pathway relevant to tumour cell differentiation and proliferation as drug screening target spot, selectively acting, in these specific target spots, possesses the important directions that pilot compound efficient, low toxicity character has become current antitumor drug research and development simultaneously; The successful listing of the targeted drugs such as Herceptin (trastuzumab), imatinib (imatinib), Gefitinib (gefitinib) and erlotinib (erlotinib) is exactly typical example [2].
Shifting with regeneration is the feature of malignant tumour, is also a difficult problem for treatment malignant tumour, even the targeted drug of a new generation is also very micro-with regeneration curative effect to the transfer of tumour.Based on this; the research of Hedgehog (Hh) signal path-hedgehog path has in recent years been subject to scientific circles and has more and more paid attention to; this is not only because Hh signal path abnormal activation comprises that in many tumours the generation evolution of rodent cancer, cerebral tumor, mammary cancer, prostate cancer and some alimentary system malignant tumours has all played very important effect [3-11]; the more important thing is that Hh signal path is fetal development path; to regulation and control tumor stem cell, thereby control metastases and regeneration play an important role.
Hedgehog signal path is the intercellular signal transduction system of a high conservative, within 1980, in fruit bat, find, because can causing larva body surface, this pathway gene sudden change of fruit bat reveals the furcellas of many likeness in form hedgehogs, therefore called after hedgehog path Hedgehog (Hh) [12].Hh signal path forms [13] by Hh part, two transmembrane protein acceptor patched membrane receptor (PTCH) and smoothened transmembrane protein (SMO) and downstream transcription factor Gli albumen etc.PTCH and SMO are two kinds of transmembrane proteins that are positioned on target cell membrane, and wherein PTCH is 12 transmembrane proteins of being encoded by cancer suppressor gene PTCH, is a kind of cell surface receptor, have the dual function of isolation and transduction Hh; SMO is 7 transmembrane proteins, and structure Shang Yu g protein coupled receptor family is highly similar, has the effect of transduction Hh signal.PTCH and SMO play the effect of acceptor in Hh signal transduction process, the acceptor that wherein PTCH is Hh, and when not there is not Hh, PTCH stops SMO to insert to cytolemma, thereby suppresses the activity of SMO, and then suppresses the transcriptional expression of downstream gene; When Hh signal exists, Hh is combined with PTCH, a plurality of serine/threonine residue generation phosphorylations of induction SMO carboxyl terminal, cause SMO assemble and activate at cell surface, the SMO activating and kinesin sample molecule Costal2 (Cos2) and serine/threonine kinases fused (Fus), Suppressor offused (Sufu) form mixture and dissociate out from microtubule, form performance transcriptional activation with total length, finally cause that zinc refers to sample transcription factor Gli activation, and the latter enters and in nucleus, causes transcribing of target gene.Therefore, in Hh signal path, Hh is the starting point of this signal path, and Gli is the terminal of this signal path as transcription factor, and Hh and SMO are as the exciting factor, and PTCH, as supressor, is regulating and controlling the activity [12,14] of signal path.
Transmembrane protein acceptor SMO is as the key members of Hh signal path, it is the transcriber in Hh signal path, it can convert intracellular Gli1 signal to extracellular Hh signal, thereby active cell core is intragentic, transcribes, and Hh signal path is had to activation [15].Most and Hh cell pathway activate the functional sudden change that all exists SMO in the generation, evolution of relevant tumour cell.Small molecules SMO protein antagonist is specific inhibition Hh signal path by antagonism SMO, and Hh signal path at normal adult in inactivated state, so antagonist can not have side effects to other positions of body, this is the theoretical basis of the magnetic target therapy feasibility of tumour.Therefore, SMO albumen has become one of target spot attracting people's attention most in current antitumor drug research and development, the synthetic research and development focus of Ge great drugmaker in the world that also becomes of the small molecular antagonists of target SMO albumen.
Have at least now the small molecular antagonists (comprising following three compounds) of 5 target SMO albumen carrying out clinical trial, the small molecules SMO antagonist GDC-0449 of the common research and development of U.S. Genentech company and Curis company, the treatment [16] for rodent cancer patient in late period by the FDA of U.S. food Drug Administration approval in January, 2012.This proof small molecules SMO antagonist has good using value and market outlook as the research and development of anti-cancer agent.
Figure BDA0000392128440000021
Reference
1.Jemal,A.;Siegel,R.;Weingerg.R.A.Cancer?statistics,2010.CA..Cancer?J.Cli.,2010,144,277-300.
2.Workman,P.;Collins,I.Modern?Cancer?Drug?Discovery:Integrating?Targets,Technologies?and?Treatments.In?Cancer?Drug?Design?and?Discovery,1st?ed.;Neidle,S.,Ed.;Elsevier:New?York,2008;pp3-38.
3.di?Magliano,M.P.;Hebrok,M.Hedgehog?signalling?in?cancer?formation?and?maintenance.Nat.Rev.Cancer2003,3,903–911.
4.Beachy,P.A.;Karhadkar,S.S.;Berman,D.M.Tissue?repair?and?stem?cell?renewal?in?carcinogenesis.Nature?2004,432,324–331.
5.Dahmane,N.;Lee,J.;Robins,P.;Heller,P.;Ruizi?Altaba,A.Activation?of?the?transcription?factor?Gli1?and?the?sonic?Hedgehog?signaling?pathway?in?skin?tumours.Nature?1997,389,876–881.
6.Hutchin,M.E.;Kariapper,M.S.T.;Gratchtchouk,M.;Wang,A.;Wei,L.;Cummings,D.;Liu,J.;Michael,L.R.;Glick,A.;Dlugosz,A.A.Sustained?Hedgehog?signaling?is?required?for?basal?cell?carcinoma?proliferation?and?survival:Conditional?skin?tumorigenesis?recapitulates?the?hair?growth?cycle.Genes?Dev.2004,19,214–224.
7.Kubo,M.;Nakamura,M.;Tasaki,A.;Yamanaka,N.;Nakashima,H.;Nomura,M.;Kuroki,S.;Katano,M.Hedgehog?signaling?pathway?is?a?new?therapeutic?target?for?patients?with?breast?cancer.Cancer?Res.2004,64,6071–6074.
8.Berman,D.M.;Karhadkar,S.S.;Maitra,A.;Montes?de?Oca,R.;Gerstenblith,M.R.;Briggs,K.;Parker,A.R.;Shimada,Y.;Eshleman,J.R.;Watkins,D.N.;Beachy,P.A.Widespread?requirement?for?Hedgehog?ligand?stimulation?in?growth?of?digestive?tract?tumors.Nature?2003,425,846–851.
9.Goodrich,L.V.;Scott,M.P.Hedgehog?and?Patched?in?neural?development?and?disease.Neuron?1998,21,1243–1257.
10.Stecca,B.;Mas.,C.;Clement,V.;Zbinden,M.;Correa,R.;Piguet,V.;Beermann,F.;Ruiz,A.Melanomas?require?Hedgehog-Gli?signaling?regulated?by?interactions?between?Gli1?and?the?RAS-MEK/AKT?pathways.Proc.Natl.Acad.Sci.U.S.A.2007,104,5895–5900.
11.Thayer,S.P.;Pasca?di?Magliano,M.;Heiser,P.W.;Nielsen,C.M.;Roberts,D.J.;Lauwers,G.Y.;Qi,Y.P.;Gysin,S.;Fernandez-del?Castillo,C.;Yajnik,V.;Antoniu,B.;McMahon,M.;Warshaw,A.L.;Hebrok,M.Hedgehog?is?an?early?and?late?mediator?of?pancreatic?cancer?tumorigenesis.Nature?2003,425,851–856.
12.Lum,L.;Beachy,P.A.The?Hedgehog?response?network:sensors,witches,and?routers.Science?2004,304,1755–1759.
13.Beachy,P.A.;Karhadkar,S.S.;Berman,D.M.Tissue?repair?and?stem?cell?renewal?in?carcinogenesis.Nature?2004,432,324–331.
14.Pasca?di?Magliano,M.;Hebrok,M.Hedgehog?signalling?in?cancer?formation?and?maintenance.Nat.Rev.Cancer?2003,3,903–911.
15.Romer,J.T.;Kimura,H.;Magdaleno,S.;Sasai,K.;Fuller,C.;Baines,H.;Connelly,M.;Stewart,C.F.;Gould,S.;Rubin,L.L.;Curran,T.Suppression?of?the?Shh?pathway?using?a?small?molecule?inhibitor?eliminates?medulloblastoma?in?Ptc1(+/-)p53(-/-)mice.Cancer?Cell?2004,6,229–240.
16.Curis?Pharmaceuticals?press?release:
http://investors.curis.com/releasedetail.cfm?ReleaseID=643756
Summary of the invention
Defect in view of above-mentioned prior art existence, the object of the invention is to propose a kind of new antitumoral compounds of blocking the pyrimidine skeleton of transmembrane protein acceptor SMO, can block hedgehog path Hedgehog, thereby suppress cellular abnormality, increase, blocking-up tumour cell shifts regeneration.
Object of the present invention is achieved by the following technical programs:
Pyrimidine skeleton has a new antitumoral compounds for hedgehog path antagonistic activity, comprises this compound and pharmacy acceptable salt thereof, various isotropic substance, various isomer or various crystalline structure, has the structure shown in general formula I:
Figure BDA0000392128440000041
Wherein, X is five yuan or hexa-atomic aromatic nucleus, fragrant heterocycle, heterocycle, and the substitutive derivative n of described ring is 0,1,2,3,4,5 or 6, R1, R2, R3, R4, R5, R6 is independently selected from respectively: hydrogen atom, halogen, alkane is for halogen, cyano group, alkane is for cyano group, trifluoromethyl, alkyl, thiazolinyl, alkynyl, amino, O, hydroxyl, S, sulfydryl, alkoxyl group, fat base, amide group, urea groups, oxo urea groups, thioureido, sulfuryl, sulfoxide group, sulfahydantoin, azido-, alkane is for thiazolinyl, alkane is for alkynyl, alkane is for amino, alkane is for hydroxyl, alkane is for fat base, alkane is for sulfuryl, alkane is for sulfoxide group, alkane is for sulfahydantoin, alkane is for azido-, cyclic alkyl, ring-type thiazolinyl, 3-12 heterocycle, aromatic nucleus or 5-12 virtue heterocycle or the substituting group of rolling into a ball containing heteroatom functional.
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, preferably, this compound and pharmacy acceptable salt thereof, various isotropic substance, various isomer or various crystalline structure, comprise general formula I I or general formula III structure:
Figure BDA0000392128440000042
Wherein: A is nitrogen-atoms or C-R7, n is 0,1,2,3,4,5 or 6, R1, R2, R3, R4, R5, R6, R7 is independently selected from respectively: hydrogen atom, halogen, alkane is for halogen, cyano group, alkane is for cyano group, trifluoromethyl, alkyl, thiazolinyl, alkynyl, amino, O, hydroxyl, S, sulfydryl, alkoxyl group, fat base, amide group, urea groups, oxo urea groups, thioureido, sulfuryl, sulfoxide group, sulfahydantoin, azido-, alkane is for thiazolinyl, alkane is for alkynyl, alkane is for amino, alkane is for hydroxyl, alkane is for fat base, alkane is for sulfuryl, alkane is for sulfoxide group, alkane is for sulfahydantoin, alkane is for azido-, cyclic alkyl, ring-type thiazolinyl, 3-12 heterocycle, aromatic nucleus or 5-12 virtue heterocycle or the substituting group of rolling into a ball containing heteroatom functional.
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, preferred:
Described alkyl is alkyl or the substituted hydrocarbon radical of saturated straight chain, side chain, ring-type, double-ring or the Spirocyclic of 1-10 carbon atom composition;
Described thiazolinyl is alkyl or the substituted hydrocarbon radical of the straight chain that contains at least one carbon-carbon double bond, side chain, ring-type, double-ring or the Spirocyclic of 1-10 carbon atom composition;
Described alkynyl is alkyl or the substituted hydrocarbon radical of the straight chain, side chain, ring-type, double-ring or the Spirocyclic that contain at least one carbon carbon triple bond of 1-10 carbon atom composition;
The substituting group of the monocycle that described fragrant cyclic group is aromaticity, many rings or heterocyclic substituent and substitutive derivative thereof, and the cyclic substituents derivative with saturated rings;
Described heterocyclic radical is monocycle, dicyclo, three ring or the volution substituting groups of the nonaromatic combination that comprises an atom in nitrogen, oxygen and sulphur or a plurality of atoms, and the cyclic substituents of their various oxidation state;
The described substituting group containing heteroatom functional group is the halogeno-group containing F, Cl, Br or I or the substituting group that comprises the one or more atoms in nitrogen, oxygen, sulphur and phosphorus, and their various oxidation state, and the quaternary ammonium salt of nitrogen.
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, preferably, described R1, R2, R3, R4, R5, R6, R7 is independently selected from respectively: hydrogen atom, alkyl, thiazolinyl, alkynyl, fragrant cyclic group or heterocyclic radical that hydrogen atom is replaced by halogeno-group, cyano group, amino, hydroxyl, sulfydryl, alkoxyl group, ester group, sulfuryl, sulfoxide group, sulfahydantoin or azido-, and cyclic alkyl, ring-type thiazolinyl, 3-12 unit's heterocyclic radical or 5-12 membered aromatic heterocycle base; The alkyl that described hydrogen atom is replaced by halogeno-group is preferably trifluoromethyl.
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, and preferred, the structure of substituent X is any one in lower array structure, wherein between pentacyclic structure and between the structure of six-ring, is respectively bioequivalence body:
Figure BDA0000392128440000051
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, and preferred, it comprises following compounds, and pharmacy acceptable salt, various isotropic substance, various isomer or various crystalline structure:
Figure BDA0000392128440000052
Figure BDA0000392128440000071
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, and preferred, the methylamino in compound or substituted methylamine base replace with any one in following amine and analogue thereof:
Figure BDA0000392128440000081
Above-mentioned a kind of pyrimidine skeleton has the new antitumoral compounds of hedgehog path antagonistic activity, and preferred, it comprises following compound:
Figure BDA0000392128440000082
Figure BDA0000392128440000101
Figure BDA0000392128440000111
The present invention also provides a kind of antitumor medicine composition, comprises the combination that at least two kinds of compounds in new antitumoral compounds, its pharmacy acceptable salt, various isotropic substance, various isomer or the various crystalline structure that the above-mentioned pyrimidine skeleton with formula I structure has hedgehog path antagonistic activity form.
The present invention also provides a kind of combined utilization composition of antitumor drug, this combined utilization composition be above-mentioned pyrimidine skeleton have the new antitumoral compounds of hedgehog path antagonistic activity and pharmaceutical composition thereof respectively with cis-platinum, taxol, camptothecine, Herceptin, imatinib mesylate, imatinib, Gefitinib, erlotinib, lapatinibditosylate in one or more combination carry out the composition that combined utilization obtains.
The application of the combined utilization composition that the present invention also provides new antitumoral compounds, antitumor medicine composition or antitumor drug that above-mentioned pyrimidine skeleton has hedgehog path antagonistic activity in the medicine of preparation treatment tumour, described tumour comprises liver cancer, lung cancer, the rectum cancer, cervical cancer, cancer of pancreas, breast cancer, cancer of the stomach, oral carcinoma, the esophageal carcinoma, nasopharyngeal carcinoma, skin carcinoma, osteocarcinoma, the combination of one or more in kidney and leukemia.
Outstanding effect of the present invention is: a kind of pyrimidine skeleton of the present invention has the new antitumoral compounds of hedgehog path antagonistic activity, by blocking-up transmembrane protein acceptor SMO, can block hedgehog path Hedgehog, thereby suppress cellular abnormality, increase, blocking-up tumour cell shifts regeneration.
Below, the specific embodiment of the present invention is described in further detail, so that technical solution of the present invention is easier to understand, grasp just in conjunction with the embodiments.
embodiment
Below by specific embodiment, method of the present invention is described, but the present invention is not limited thereto.Experimental technique described in following embodiment, if no special instructions, is ordinary method; Described reagent and material, if no special instructions, all can obtain from commercial channels.Solvent for use and medicine are analytical pure or chemical pure; Solvent all passes through re-distillation before use; Anhydrous solvent is all processed according to standard method or literature method.Column chromatography silica gel (100-200 order) and tlc silica gel (GF254) are Haiyang Chemical Plant, Qingdao and chemical plant, Yantai product; If not otherwise specified, all adopt sherwood oil (60-90 ℃)/ethyl acetate (v/v) as eluent; The ethanolic soln of iodine or phospho-molybdic acid for developer; All extraction solvent unexplained reference are all used anhydrous Na 2sO 4dry.Bruck-400 type nuclear magnetic resonance analyser record for 1H-NMR, TMS is interior mark.U.S. Agilent company 1100 type HPLC-ESI-MSn combined instrument (LC-MSD Trap) records for LC-MS, diode-array detector (DAD), detects wavelength 214nm and 254nm, ion trap mass spectrometry (ESI source).HPLC post is Agela Durashell C18 (4.6 * 50mm, 3.5 μ m); Moving phase is 0.1%NH 4hCO 3the aqueous solution: acetonitrile (in 5 minutes from 5: 95 to 95: 5); Flow velocity is 1.8mL/min.
Embodiment 1
The present embodiment provides a kind of new antitumoral compounds A1, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000121
1) intermediate A 1-2's is synthetic:
By in the molten 40 milliliters of DMFs of 4-tertbutyloxycarbonyl piperidone (10g, 50.2mmol), add while stirring DMF dimethylacetal (6g, 50mmol), finish, 80 ℃ are reacted 12 hours.Be cooled to room temperature, join in ethyl acetate (150mL) and water (50mL), saturated aqueous common salt for organic phase (50mL) washes twice, and anhydrous sodium sulfate drying filters, and revolves and steams to such an extent that an orange crude product (13g) is directly cast single step reaction.
2) intermediate A 1-3's is synthetic:
Under normal temperature, by sulfuric acid half methyl-thiourea (6.98g, 25.1mmol) and sodium ethylate (3.28g, 40mmol) be dissolved in 40 milliliters of ethanol, stir after half an hour, add step synthetic intermediate A 1-2(13g, 50.2mmol) 10 milliliters of ethanolic solns, backflow 12h, be cooled to room temperature, underpressure distillation, enriched material washes with water, ethyl acetate extraction, organic phase is washed with saturated common salt, after anhydrous sodium sulfate drying filters, and evaporated under reduced pressure, through column chromatography refining (moving phase is ethyl acetate: methylene dichloride=1:25) an orange (7.38g, 52%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.24 (s, 1H), 4.50 (s, 2H), 3.69 (t, J=5.9Hz, 2H), 2.86 (t, J=5.8Hz, 2H), 2.52 (s, 3H), 1.47 (s, 9H).
3) intermediate A 1-4's is synthetic:
By A1-3(7.38g, 26.3mmol) after being dissolved in 50 milliliters of methylene dichloride of 0 ℃, slowly add while stirring metachloroperbenzoic acid (75%, 12.5g, 54.5mmol), after stirring at normal temperature 12 hours, the saturated aqueous solution (10mL) that adds sodium bicarbonate (10mL) and Sulfothiorine, stirring at normal temperature 2h, organic phase underpressure distillation is concentrated, through column chromatography refining (moving phase is sherwood oil: ethyl acetate=3:1) a white solid (5.5g, 67%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.63 (s, 1H), 4.70 (s, 2H), 3.79 (t, J=5.9Hz, 2H), 3.33 (s, 3H), 3.09 (t, J=5.8Hz, 2H), 1.49 (s, 9H).
4) intermediate A 1-5's is synthetic:
A1-4(1g, 3.19mmol) and methylamine alcohol solution (21%, 1mL) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (700mg, 83%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.03 (s, 1H), 4.41 (s, 2H), 3.67 (t, J=5.8Hz, 2H), 3.52 (s, 3H), 2.73 (t, J=5.7Hz, 2H), 1.56 (s, 9H).
5) intermediate A 1-6's is synthetic:
By A1-5(700mg, 2.65mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins in saturated sodium bicarbonate aqueous solution in (5 milliliters) and methylene dichloride (20 milliliters), saturated aqueous common salt for organic phase (5mL) is washed, anhydrous sodium sulfate drying is spin-dried for to obtain a white solid (420mg, 96%) after filtering.
6) intermediate A 1-9's is synthetic:
By 2, the chloro-4-boric acid of 5-bis-pyridine (7.56g, 40mmol) He 3,5-dimethyl-2-bromopyridine (5.62g, 30mmol) joins in the mixed solution of 60 milliliters of dioxane and 12 ml waters, then adds Pd(dppf) Cl2(1.35g, 1.7mmol) He three water potassiumphosphate (16.2g, 60mmol), nitrogen exchange three times for reaction system, reflux is spent the night.Reaction solution cool to room temperature, adds 50 ml waters to filter, and filtrate extracts three times with methylene dichloride (50mL), and organic phase is filtered with anhydrous sodium sulfate drying, and filtrate was spin-dried for post (sherwood oil: product ethyl acetate=10:1) (3.1g, 41%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.46 (s, 1H), 8.37 (s, 1H), 7.47 (s, 1H), 7.33 (s, 1H), 2.39 (s, 3H), 2.16 (s, 3H).
7) product A 1 is synthetic:
A1-6 (100mg, 0.610mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (45mg, 60%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.11 (s, 1H), 7.43 (s, 1H), 6.65 (s, 1H), 4.54 (s, 2H), 3.90 (s, 2H), 3.00 (d, J=5.0Hz, 3H), 2.88 (s, 2H), 2.37 (s, 3H), 2.17 (s, 3H); ESI-MS (m/z): 380.8[M+1] +.
The solid spectrum analysis of gained is
Embodiment 2
The present embodiment provides a kind of new antitumoral compounds A2, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000141
1) intermediate A 2-1's is synthetic:
A1-4(1g, 3.19mmol) and ethylamine solution (71%, 1mL) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (400mg, 45%).
2) intermediate A 2-2's is synthetic:
By A2-1(400mg, 1.44mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), and saturated aqueous common salt for organic phase (10mL) is washed, after filtering, anhydrous sodium sulfate drying obtains a white solid (250mg, 97%).
3) product A 2 is synthetic:
A2-2 (100mg, 0.562mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (25mg, 32%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.34 (s, 1H), 8.22 (s, 1H), 8.08 (s, 1H), 7.41 (s, 1H), 6.63 (s, 1H), 4.52 (s, 2H), 3.89 (t, J=5.6Hz, 2H), 3.47-3.37 (m, 2H), 2.85 (t, J=5.8Hz, 2H), 2.36 (s, 3H), 2.16 (s, 3H), 1.21 (t, J=7.2Hz, 3H); ESI-MS (m/z): 394.9[M+1] +.
The solid spectrum analysis of gained is
Embodiment 3
The present embodiment provides a kind of new antitumoral compounds A3, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000151
1) intermediate A 3-1's is synthetic:
A1-4(1g, 3.19mmol) and cyclopropylamine (300mg, 5.26mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (460mg, 50%).
2) intermediate A 3-2's is synthetic:
By A3-1(460mg, 1.58mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and enriched material joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), and saturated aqueous common salt for organic phase (10mL) is washed, after filtering, anhydrous sodium sulfate drying obtains a white solid (270mg, 90%).
3) product A 3 is synthetic:
A3-2 (100mg, 0.345mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (30mg, 40%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.39 (s, 1H), 8.23 (s, 1H), 8.17 (s, 1H), 7.42 (s, 1H), 6.65 (s, 1H), 4.55 (s, 2H), 3.90 (t, J=5.6Hz, 2H), 2.88 (t, J=5.8Hz, 2H), 2.77 (m, 1H), 2.42 (s, 3H), 2.21 (s, 3H), 1.29 (s, 1H), 0.87-079 (m, 2H), 0.62-0.55 (m, 2H); ESI-MS (m/z): 406.9[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000152
Embodiment 4
The present embodiment provides a kind of new antitumoral compounds A4, and the synthetic method of this compound is as follows:
1) intermediate A 4-1's is synthetic:
A1-4(1g, 3.19mmol) and Pyrrolidine (300mg, 4.22mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (600mg, 62%).
2) intermediate A 4-2's is synthetic:
By A4-1(600mg, 1.97mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), saturated aqueous common salt for organic phase (10mL) is washed, with anhydrous sodium sulfate drying, after filtering and concentrating, obtain a white solid (360mg, 89%).
3) product A 4 is synthetic:
A4-2 (100mg, 0.490mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (37mg, 47%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.42 (s, 1H), 6.63 (s, 1H), 4.51 (s, 2H), 3.89 (t, J=5.6Hz, 2H), 3.56 (t, J=6.5Hz, 4H), 2.89 (t, J=5.8Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 1.97 (t, J=6.6Hz, 4H); ESI-MS (m/z): 420.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000162
Embodiment 5
The present embodiment provides a kind of new antitumoral compounds A5, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000171
1) intermediate A 5-1's is synthetic:
A1-4(1g, 3.19mmol) with N-methyl 2-monoethanolamine (480mg, 6.39mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (280mg, 28%).
2) intermediate A 5-2's is synthetic:
By A5-1(280mg, 0.91mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), and saturated aqueous common salt for organic phase (10mL) is washed, after filtering, anhydrous sodium sulfate drying obtains a white solid (180mg, 95%).
3) product A 5 is synthetic:
A5-2 (80mg, 0.384mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (20mg, 24%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.33 (s, 1H), 8.21 (s, 1H), 8.08 (s, 1H), 7.41 (s, 1H), 6.63 (s, 1H), 4.51 (s, 2H), 3.87 (s, 4H), 3.74 (s, 2H), 3.19 (s, 3H), 2.86 (s, 2H), 2.35 (s, 3H), 2.15 (s, 3H); ESI-MS (m/z): 424.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000172
Embodiment 6
The present embodiment provides a kind of new antitumoral compounds A6, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000181
1) intermediate A 6-1's is synthetic:
A1-4(1g, 3.19mmol) with 4-hydroxy piperidine (650mg, 6.39mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=2:1) a white solid (400mg, 37.5%).
2) intermediate A 6-2's is synthetic:
By A6-1(400mg, 1.2mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), saturated aqueous common salt for organic phase (10mL) is washed, with anhydrous sodium sulfate drying, after filtering and concentrating, obtain a white solid (210mg, 79%).
3) product A 6 is synthetic:
A6-2 (200mg, 0.85mmol), cesium fluoride (300mg, 1.98mmol) and A1-9(80mg, 0.31mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (30mg, 21%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.37 (s, 1H), 8.24 (s, 1H), 8.12 (s, 1H), 7.47 (s, 1H), 6.66 (s, 1H), 4.53 (s, 2H), 4.43 (s, 2H), 3.40 (s, 3H), 3.31 (s, 2H), 2.89 (s, 2H), 2.39 (s, 3H), 2.25 (s, 3H), 1.94 (s, 2H), 1.55 (s, 2H); ESI-MS (m/z): 450.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000182
Embodiment 7
The present embodiment provides a kind of new antitumoral compounds A7, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000191
1) intermediate A 7-1's is synthetic:
A1-4(1g, 3.19mmol) and morpholine (700mg, 8.0mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=2:1) a white solid (760mg, 75%).
2) intermediate A 7-2's is synthetic:
By A7-1(700mg, 2.3mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), saturated aqueous common salt for organic phase (10mL) is washed, with anhydrous sodium sulfate drying, after filtering and concentrating, obtain a white solid (434mg, 83%).
3) product A 7 is synthetic:
A6-2 (50mg, 0.23mmol), cesium fluoride (300mg, 1.98mmol) and A1-9(20mg, 0.079mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (10mg, 29%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.40 (s, 1H), 8.25 (s, 1H), 8.15 (s, 1H), 7.52 (s, 1H), 6.69 (s, 1H), 4.56 (s, 2H), 3.91 (s, 3H), 3.78-3.78 (m, 8H), 2.90 (s, 2H), 2.41 (s, 3H), 2.21 (s, 3H); ESI-MS (m/z): 436.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000192
Embodiment 8
The present embodiment provides a kind of new antitumoral compounds A8, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000201
1) intermediate A 8-1's is synthetic:
A1-4(854mg, 2.728mmol) and 2,6-lupetazin (950mg, 8.333mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, and through column chromatography, refining (moving phase is sherwood oil: ethyl acetate=5:1 to methylene dichloride to enriched material: methyl alcohol=10:1) must a white solid (245mg, 26.5%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 7.97 (s, 1H), 4.54 (d, J=13.2Hz, 2H), 4.33 (s, 2H), 3.59 (s, 2H), 2.67 (s, 2H), 2.38-2.29 (m, 2H), 1.97 (s, 2H), 1.41 (s, 9H), 1.06 (d, J=6.0Hz, 6H).
2) intermediate A 8-2's is synthetic:
By A8-1(245mg, 0.706mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a yellow solid (100mg, 57.3%).
3) product A 8 is synthetic:
A8-2 (90mg, 0.364mmol), cesium fluoride (43mg, 0.283mmol) and A1-9(31mg, 0.123mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (36mg, 63.4%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.29 (s, 1H), 8.17 (s, 1H), 8.06 (s, 1H), 7.36 (s, 1H), 6.59 (s, 1H), 4.82-4.59 (m, 2H), 4.48 (s, 2H), 3.84 (t, J=5.2Hz, 2H), 3.08 (s, 4H), 2.82 (t, J=6.0Hz, 2H), 2.31 (s, 3H), 2.11 (s, 3H), 1.50 (s, 6H); ESI-MS (m/z): 463.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000202
Embodiment 9
The present embodiment provides a kind of new antitumoral compounds A9, and the synthetic method of this compound is as follows:
1) intermediate A 9-1's is synthetic:
A1-4(1g, 3.195mmol) with methylethylolamine solution (27%-32%, 1g) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material obtains a yellow oil (500mg, 59.3%) through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1 is to 1:1).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.03 (s, 1H), 4.40 (s, 2H), 4.10 (q, J=7.1Hz, 1H), 3.67 (t, J=5.6Hz, 2H), 2.97 (d, J=5.2Hz, 3H), 2.73 (t, J=5.6Hz, 2H), 1.47 (s, 9H).
2) intermediate A 9-2's is synthetic:
A9-1 (300mg, 1.14mmol) is dissolved in the methylene dichloride of 10mL, at 0 ℃, adds triethylamine (487mg, 4.82mmol), dropwise add subsequently methylene dichloride (5mL) solution of methylsulfonyl chloride (360mg, 3.16mmol).At 0 ℃, stir 1 hour, desolventizing is revolved in decompression, solute through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a colorless oil (321mg, 82.7%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.23 (s, 1H), 4.46 (s, 2H), 3.65 (t, J=5.8Hz, 2H), 3.43 (s, 3H), 3.40 (s, 3H), 2.82 (t, J=5.6Hz, 2H), 1.41 (s, 9H).
3) intermediate A 9-3's is synthetic:
By A9-2(321mg, 0.94mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a white solid (76mg, 33.5%).Its chemical shift is as follows: 1h-NMR (400MHz, DMSO-d6) δ 8.20 (s, 1H), 3.99 (s, 2H), 3.45 (s, 3H), 3.42 (s, 3H), 3.24 (t, J=6.4Hz, 2H), 2.89 (t, J=5.8Hz, 2H).
4) product A 9 is synthetic:
A9-3 (76mg, 0.364mmol), cesium fluoride (64mg, 0.42mmol) and A1-9(53mg, 0.21mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (3 mg, 3.1%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.33 (s, 1H), 8.31 (s, 1H), 8.19 (s, 1H), 7.47 (s, 1H), 6.66 (s, 1H), 4.62 (s, 2H), 3.88 (t, J=5.6Hz, 2H), 3.47 (s, 3H), 3.44 (s, 3H), 2.97 (t, J=5.6Hz, 2H), 2.35 (s, 3H), 2.15 (s, 3H); ESI-MS (m/z): 458.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000221
Embodiment 10
The present embodiment provides a kind of new antitumoral compounds A10, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000222
1) intermediate A 10-1's is synthetic:
Pyrazoles (435mg, 6.4mmol) is dissolved in the tetrahydrofuran (THF) of 15mL, at 0 ℃, adds sodium hydride (80%, 221mg, 7.36mmol), at room temperature stir 15 minutes, then add A1-4 (1g, 3.2mmol), stir 1 hour at 0 ℃.Add saturated aqueous ammonium chloride cancellation, desolventizing is revolved in decompression, add methylene dichloride (150mL) and water (100mL), after organic phase is filtered with anhydrous sodium sulfate drying, revolve desolventizing, solute through column chromatography refining (moving phase is sherwood oil: ethyl acetate=1:1) a white solid (610mg, 63.4%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.52 (s, 1H), 8.40 (s, 1H), 7.76 (s, 1H), 6.43 (s, 1H), 4.57 (s, 2H), 3.72 (t, J=5.8Hz, 2H), 2.99 (t, J=5.6Hz, 2H), 1.45 (s, 9H).
2) intermediate A 10-2's is synthetic:
By A10-1 (610mg, 2.03mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a white solid (173mg, 42.5%).
3) product A 10 is synthetic:
A10-2 (140mg, 0.70mmol), cesium fluoride (70mg, 0.46mmol) and A1-9(59mg, 0.23mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (22mg, 22.6%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.56 (s, 1H), 8.51 (s, 1H), 8.38 (s, 1H), 8.25 (s, 1H), 7.80 (s, 1H), 7.52 (s, 1H), 6.74 (s, 1H), 6.47 (s, 1H), 4.76 (s, 2H), 3.97 (s, 2H), 3.16 (s, 2H), 2.40 (s, 3H), 2.20 (s, 3H); ESI-MS (m/z): 417.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000231
Embodiment 11
The present embodiment provides a kind of new antitumoral compounds A11, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000232
1) intermediate A 11-1's is synthetic:
A1-4(625mg, 2mmol) and Isopropylamine (2g, 33.9mmol) be under agitation dissolved in successively in the trimethyl carbinol (15mL), be heated to reflux, after 36 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material obtains a yellow solid (365mg, 62.6%) through column chromatography refining (moving phase is sherwood oil: ethyl acetate=3:1 is to 1:1).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 7.97 (s, 1H), 4.75 (d, J=7.2Hz, 1H), 4.35 (s, 2H), 4.04 (m, 1H), 3.61 (t, J=5.2Hz, 2H), 2.66 (s, 2H), 1.42 (s, 9H), 1.16 (d, J=6.4Hz, 6H).
2) intermediate A 11-2's is synthetic:
By A11-1(365mg, 1.25mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a yellow solid (157mg, 65.4%).
3) product A 11 is synthetic:
A11-2 (147mg, 0.77mmol), cesium fluoride (78mg, 0.51mmol) and A1-9(65mg, 0.255mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (24mg, 22.9%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.09 (s, 1H), 7.43 (s, 1H), 6.64 (s, 1H), 4.93 (d, J=7.6Hz, 1H), 4.53 (s, 2H), 4.13 (m, 1H), 3.90 (s, 2H), 2.84 (t, J=5.6Hz, 2H), 2.36 (s, 3H), 2.18 (s, 3H), 1.23 (d, J=6.4Hz, 6H); ESI-MS (m/z): 408.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000241
Embodiment 12
The present embodiment provides a kind of new antitumoral compounds A12, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000242
1) intermediate A 12-1's is synthetic:
In tube sealing by A1-4(1g, 3.2mmol) and TERTIARY BUTYL AMINE (1.4g, 19.2mmol) be dissolved in successively in the trimethyl carbinol (15mL), be heated to 80 ℃, after 54 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a yellow oil (130mg, 13.3%). 1H-NMR(400MHz,CDCl 3)δ7.97(s,1H),4.98(s,1H),4.37(s,2H),3.65(s,2H),2.68(s,2H),1.45(s,9H),1.39(s,9H)。
2) intermediate A 12-2's is synthetic:
By A12-1(130mg, 0.42mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a yellow oil (43mg, 52.4%).
3) product A 12 is synthetic:
A12-2 (43mg, 0.21mmol), cesium fluoride (32mg, 0.21mmol) and A1-9(27mg, 0.105mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (15mg, 33.3%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.06 (s, 1H), 7.42 (s, 1H), 6.63 (s, 1H), 5.15 (s, 1H), 4.51 (s, 2H), 3.88 (t, J=5.2Hz, 2H), 2.84 (t, J=5.8 Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 1.43 (s, 9H); ESI-MS (m/z): 422.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000251
Embodiment 13
The present embodiment provides a kind of new antitumoral compounds A13, and the synthetic method of this compound is as follows:
1) intermediate A 13-1's is synthetic:
By A1-4(1g, 3.2mmol) be dissolved in the aniline of 10mL, be heated to 100 ℃, after 48 hours, be cooled to room temperature, through column chromatography refining (moving phase is sherwood oil: ethyl acetate=8:1) a brown oil (280mg, 26.9%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.17 (s, 1H), 7.63 (s, 1H), 7.61 (s, 1H), 7.35 (s, 1H), 7.33 (s, 1H), 7.31 (s, 1H), 4.49 (s, 2H), 3.73 (t, J=5.8Hz, 2H), 2.84 (t, J=5.8Hz, 2H), 1.50 (s, 9H).
2) intermediate A 13-2's is synthetic:
By A13-1(280mg, 0.86mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a brown solid (140mg, 72.2%).
3) product A 13 is synthetic:
A13-2 (80mg, 0.35mmol), cesium fluoride (81mg, 0.53mmol) and A1-9(45mg, 0.178mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (26mg, 33.1%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.41 (s, 1H), 8.26 (d, J=5.2Hz, 2H), 7.64 (s, 1H), 7.62 (s, 1H), 7.55 (s, 1H), 7.34 (t, J=7.2Hz, 2H), 7.06 (t, J=7.8Hz, 1H), 6.73 (s, 1H), 4.63 (s, 2H), 3.95 (s, 2H), 3.01 (t, J=5.4Hz, 2H), 2.42 (s, 3H), 2.22 (s, 3H); ESI-MS (m/z): 442.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000261
Embodiment 14
The present embodiment provides a kind of new antitumoral compounds A14, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000262
1) intermediate A 14-1's is synthetic:
By A1-3(1g, 3.56mmol) join the hydrogenchloride ethyl acetate solution ethyl acetate solution (5mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a brown oil (600mg, 93.2%).
2) product A 14 is synthetic:
A14-1 (480mg, 2.65mmol), cesium fluoride (808mg, 5.32mmol) and A1-9(335mg, 1.33mmol) under agitation condition, be dissolved in methyl-sulphoxide (7mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (100mL) and water (50mL), saturated aqueous common salt for organic phase (50mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow oil (270mg, 50.9%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.38 (s, 1H), 8.33 (s, 1H), 8.25 (s, 1H), 7.48 (s, 1H), 6.70 (s, 1H), 4.67 (s, 2H), 3.93 (t, J=5.1Hz, 2H), 3.01 (t, J=5.4Hz, 2H), 2.56 (s, 3H), 2.40 (s, 3H), 2.20 (s, 3H); ESI-MS (m/z): 397.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000263
Embodiment 15
The present embodiment provides a kind of new antitumoral compounds A15, and the synthetic method of this compound is as follows:
By A14(320mg, 0.81mmol) be dissolved in the tetrahydrofuran (THF) of 10mL, peroxosulphuric hydrogen potassium (546mg, 1.78 mmol) is dissolved in the water of 2mL.Two solution are merged, stir and spend the night at normal temperatures.Add ethyl acetate (100mL) and water (50mL), saturated aqueous common salt for organic phase (50mL) is washed, and anhydrous sodium sulfate drying revolves desolventizing after filtering, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow oil (150mg, 43.2%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.69 (s, 1H), 8.35 (s, 1H), 8.25 (s, 1H), 7.44 (s, 1H), 6.74 (s, 1H), 4.87 (s, 2H), 3.97 (t, J=5.6Hz, 2H), 3.35 (s, 3H), 3.22 (t, J=5.8Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H); ESI-MS (m/z): 429.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000271
Embodiment 16
The present embodiment provides a kind of new antitumoral compounds A16, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000272
By A15(40mg, 0.093mmol) with cyclopropyl methylamine (14mg, 0.197mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (15.2mg, 38.9%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.09 (s, 1H), 7.42 (s, 1H), 6.64 (s, 1H), 5.16 (t, J=6.0Hz, 1H), 4.52 (s, 2H), 3.89 (t, J=5.0Hz, 2H), 3.25 (t, J=6.2Hz, 2H), 2.86 (t, J=5.4Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 1.07 (m, 1H), 0.51 (d, J=7.6Hz, 2H), 0.24 (d, J=4.8Hz, 2H); ESI-MS (m/z): 420.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000273
Embodiment 17
The present embodiment provides a kind of new antitumoral compounds A17, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000274
By A15(44mg, 0.103mmol) with 3-pyrrolidinol (36mg, 0.414mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (7.4mg, 16.5%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.34 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.42 (s, 1H), 6.64 (s, 1H), 4.57 (s, 1H), 4.51 (s, 2H), 3.89 (t, J=5.2Hz, 2H), 3.73-3.62 (m, 2H), 2.88 (t, J=5.8Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 2.13-2.01 (m, 2H); ESI-MS (m/z): 436.8[M+1] +.
The oily matter of gained is through resolving to
Figure BDA0000392128440000281
Embodiment 18
The present embodiment provides a kind of new antitumoral compounds A18, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000282
By A15(40mg, 0.093mmol) and sodium ethylate (19mg, 0.279mmol) be dissolved in the ethanol of 2mL, at 0 ℃, react 1 hour, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (20mg, 54.3%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.35 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 7.43 (s, 1H), 6.67 (s, 1H), 4.64 (s, 2H), 4.39 (q, J=7.2Hz, 2H), 3.91 (s, 2H), 2.98 (t, J=5.6Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 1.42 (t, J=7.1Hz, 3H); ESI-MS (m/z): 395.9[M+1] +.
The solid spectrum analysis of gained is
Embodiment 19
The present embodiment provides a kind of new antitumoral compounds A19, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000284
By A15 (40mg, 0.093mmol), 4-methoxyl group piperidine hydrochlorate (29mg, 0.186mmol) and triethylamine (21mg, 0.205mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (7.5mg, 17.4%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.37 (s, 1H), 8.24 (s, 1H), 8.11 (s, 1H), 7.44 (s, 1H), 6.65 (s, 1H), 4.52 (s, 2H), 4.32 (d, J=6.0Hz, 2H), 3.90 (s, 2H), 3.45 (m, 1H), 3.40 (s, 3H), 3.38-3.34 (m, 2H), 2.87 (s, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.93-1.93 (m, 2H), 1.61-1.54 (m, 2H); ESI-MS (m/z): 464.8[M+1] +.
The oily matter spectrum analysis of gained is
Figure BDA0000392128440000291
Embodiment 20
The present embodiment provides a kind of new antitumoral compounds A20, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000292
At 0 ℃, sodium hydride (80%, 9mg, 0.28mmol) is joined in the Virahol of 5mL, keep 0 ℃ of reaction 15 minutes, then by A15(40mg, 0.093mmol) join in reaction solution, keep 0 ℃ of reaction 2h, add saturated ammonium chloride solution cancellation, desolventizing is revolved in decompression, and enriched material dilutes by ethyl acetate, family's saturated common salt washing, organic phase is dry concentrated, through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (18mg, 47.4%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.36 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 7.43 (s, 1H), 6.68 (s, 1H), 5.26 (m, 1H), 4.64 (s, 2H), 3.91 (s, 2H), 2.98 (s, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.38 (d, J=4.4Hz, 6H); ESI-MS (m/z): 409.8[M+1] +.
The oily matter spectrum analysis of gained is
Figure BDA0000392128440000293
Embodiment 21
The present embodiment provides a kind of new antitumoral compounds A21, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000294
By A15(44mg, 0.10mmol) and cyclopentamine (27mg, 0.31mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, and desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (4.2mg, 9.4%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.33 (s, 1H), 8.21 (s, 1H), 8.07 (s, 1H), 7.40 (s, 1H), 6.62 (s, 1H), 5.13 (d, J=8.8Hz, 1H), 4.50 (s, 2H), 4.23 (m, 1H), 3.87 (t, J=5.8Hz, 2H), 2.83 (t, J=5.8Hz, 2H), 2.35 (s, 3H), 2.15 (s, 3H), 2.05-1.98 (m, 2H), 1.70-1.61 (m, 4H), 1.48-1.41 (m, 2H); ESI-MS (m/z): 434.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000301
Embodiment 22
The present embodiment provides a kind of new antitumoral compounds A22, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000302
By cyclopentanol (27mg, 0.31mmol) join in the tetrahydrofuran (THF) of 2mL, at 0 ℃, add sodium hydride (80%, 10mg, 0.33mmol), keep 0 ℃ of reaction 15 minutes, again by A15(43mg, 0.10mmol) join in reaction solution, keep 0 ℃ of reaction 2h, use saturated ammonium chloride solution cancellation, desolventizing is revolved in decompression, add water 30mL, by ethyl acetate (30mL * 3), extract, after organic phase is filtered with anhydrous sodium sulfate drying, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (2.3mg, 5.2%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.36 (s, 1H), 8.28 (s, 1H), 8.25 (s, 1H), 7.44 (s, 1H), 6.68 (s, 1H), 5.41 (m, 1H), 4.65 (s, 2H), 3.92 (t, J=5.0Hz, 2H), 2.99 (t, J=5.6Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.98-1.95 (m, 2H), 1.88 (s, 2H), 1.63 (s, 4H); ESI-MS (m/z): 435.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000303
Embodiment 23
The present embodiment provides a kind of new antitumoral compounds A23, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000304
By A15 (42mg, 0.098mmol), 3-hydroxyl azetidine hydrochloride (55mg, 0.5mmol) and triethylamine (60mg, 0.205mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (6.9mg, 16.8%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.35 (s, 1H), 8.24 (s, 1H), 8.13 (s, 1H), 7.43 (s, 1H), 6.65 (s, 1H), 4.86-4.67 (m, 1H), 4.54 (s, 2H), 4.39 (t, J=8.0Hz, 2H), 3.99-3.96 (m, 2H), 3.90 (t, J=5.6Hz, 2H), 2.90 (t, J=6.0Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H); ESI-MS (m/z): 422.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000311
Embodiment 24
The present embodiment provides a kind of new antitumoral compounds A24, and the synthetic method of this compound is as follows:
By cyclopropyl-carbinol (72mg, 1mmol) join in the tetrahydrofuran (THF) of 2mL, at 0 ℃, add sodium hydride (80%, 33mg, 1.1mmol), keep 0 ℃ of reaction 15 minutes, again by A15(44mg, 0.103mmol) join in reaction solution, normal-temperature reaction 3h, use saturated ammonium chloride solution cancellation, desolventizing is revolved in decompression, add water 30mL, by ethyl acetate (30mL * 3), extract, after organic phase is filtered with anhydrous sodium sulfate drying, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (2.8mg, 6.5%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.36 (s, 1H), 8.29 (s, 1H), 8.25 (s, 1H), 7.44 (s, 1H), 6.68 (s, 1H), 4.65 (s, 2H), 4.18 (d, J=7.6Hz, 2H), 3.92 (t, J=4.6Hz, 2H), 2.99 (t, J=5.6Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.32 (m, 1H), 0.61 (d, J=7.2Hz, 2H), 0.37 (d, J=4.8Hz, 2H); ESI-MS (m/z): 421.9[M+1] +.
The oily matter spectrum analysis of gained is
Figure BDA0000392128440000313
Embodiment 25
The present embodiment provides a kind of new antitumoral compounds A25, and the synthetic method of this compound is as follows:
1) intermediate A 25-1's is synthetic:
4-tertbutyloxycarbonyl piperidone (1g, 5.0mmol) is dissolved in anhydrous tetrahydro furan, and at nitrogen protection borehole cooling, to-78 ℃, lithium diisopropyl amido (3mL, 6.0mmol) is added drop-wise in above-mentioned solution at this temperature; After 30 minutes, methyl iodide (852mg, 6.0mmol) adds at-78 ℃, and reaction at room temperature continues to stir 3 hours.With saturated aqueous ammonium chloride solution cancellation, add ethyl acetate (20mL) extraction, organic phase is revolved desolventizing after filtering with anhydrous sodium sulfate drying, solute through column chromatography refining (moving phase is sherwood oil: ethyl acetate=20:1) a colourless oil liquid (500mg, 45.5%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 4.11 (m, 1H), 3.71 (m, 1H), 3.23 (m, 1H), 2.81 (br s, 1H), 2.47 (m, 3H), 1.47 (s, 9H), 1.03 (d, J=6.8Hz, 3H).
2) intermediate A 25-2's is synthetic:
By A25-1(200mg, 0.94mmol) molten 2 milliliters of DMF dimethylacetals, finish, 80 ℃ are reacted 12 hours.Be cooled to room temperature, revolve and steam to such an extent that an orange crude product is directly cast single step reaction.Under normal temperature, by sulfuric acid half methyl-thiourea (88mg, 0.47mmol) and sodium ethylate (64mg, 0.94mmol) be dissolved in 4 milliliters of ethanol, stir after half an hour, 1 milliliter of the ethanolic soln that adds the synthetic orange crude product of step, backflow 12h, is cooled to room temperature, underpressure distillation, enriched material dilute with water, ethyl acetate extraction, organic phase is washed with saturated common salt, after anhydrous sodium sulfate drying filters, evaporated under reduced pressure, through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:5) an orange (100mg, 36%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.25 (s, 1H), 3.75-3.70 (m, 3H), 3.49 (m, 1H), 2.94 (m, 1H), 2.56 (s, 3H), 1.41 (s, 9H), 1.26 (t, J=7.2Hz, 3H).
3) intermediate A 25-3's is synthetic:
By A25-2(900mg, 3.1mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (450mg, 74%) and be directly used in next step with reversed-phase preparative chromatography.
4) product A 25 is synthetic:
A25-3 (450mg, 2.3mmol), cesium fluoride (700mg, 4.6mmol) and A1-9(580mg, 2.3mmol) under agitation condition, be dissolved in methyl-sulphoxide (2.5mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (450mg, 48%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.36 (s, 1H), 8.31 (s, 1H), 8.24 (s, 1H), 7.44 (s, 1H), 6.67 (s, 1H), 4.63 (m, 2H), 3.99 (m, 1H), 3.58 (m, 1H), 3.12 (m, 1H), 2.57 (s, 3H), 2.38 (s, 3H), 2.18 (s, 3H), 1.38 (d, J=5.0Hz, 3H); ESI-MS (m/z): 411.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000321
Embodiment 26
The present embodiment provides a kind of new antitumoral compounds A26, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000331
1) intermediate A 26-1's is synthetic:
By A25(50mg, 0.12mmol) be dissolved in the mixed solvent of tetrahydrofuran (THF) and water, in ice-water bath, add potassium hydrogen persulfate (72mg, 0.24mmol), reaction at room temperature continues to stir 16 hours, remove by filter not tolerantly, filtrate concentrated post (methylene dichloride: methyl alcohol=50:1) purifying obtains product (10mg, 19%).
2) compd A 26 is synthetic:
A26-1(20mg, 0.045mmol) and cyclopropylamine (5.1mg, 0.09mmol) be under agitation dissolved in successively in the trimethyl carbinol (1mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=50:1) a yellow solid (8mg, 42%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.34 (s, 1H), 8.22 (s, 1H), 8.15 (s, 1H), 7.42 (s, 1H), 6.63 (s, 1H), 5.21 (s, 1H), 4.53 (s, 2H), 3.92 (m, 1H), 3.59 (m, 1H), 2.95 (m, 1H), 2.21 (m, 1H), 2.37 (s, 3H), 2.17 (s, 3H), 1.32 (d, J=6.8Hz, 3H), 0.87-079 (m, 2H), 0.58-0.52 (m, 2H); ESI-MS (m/z): 443.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000332
Embodiment 27
The present embodiment provides a kind of new antitumoral compounds A27, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000333
A26-1(20mg, 0.045mmol) He 2,6-lupetazin (10.3mg, 0.09mmol) be under agitation dissolved in successively in the trimethyl carbinol (1mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=50:1) a yellow solid (7mg, 32.5%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.37 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.44 (s, 1H), 6.64 (s, 1H), 4.73 (m, 2H), 4.53 (m, 2H), 4.01 (m, 1H), 3.52 (m, 1H), 3.01 (br, 3H), 2.71 (br, 2H), 2.38 (s, 3H), 2.19 (s, 3H), 1.35-1.26 (m, 9H); ESI-MS (m/z): 477.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000341
Embodiment 28
The present embodiment provides a kind of new antitumoral compounds A28, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000342
1) intermediate A 28-1's is synthetic:
By A25-2(2g, 6.8mmol) after being dissolved in 20 milliliters of methylene dichloride of 0 ℃, slowly add while stirring metachloroperbenzoic acid (75%, 3.16g, 13.6mmol), after stirring at normal temperature 12 hours, the saturated aqueous solution (5mL) that adds sodium bicarbonate (5mL) and Sulfothiorine, stirring at normal temperature 30 minutes, organic phase underpressure distillation is concentrated, through column chromatography refining (moving phase is sherwood oil: ethyl acetate=3:1) a white solid (1.5g, 67%).
2) intermediate A 28-2's is synthetic:
A28-1(250mg, 0.76mmol) and Pyrrolidine (216mg, 3.04mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (190mg, 78%).
3) intermediate A 28-3's is synthetic:
By A28-2(190mg, 0.6mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (110mg, 84%) and be directly used in next step with reversed-phase preparative chromatography.
4) product A 28 is synthetic:
A28-3 (67mg, 0.31mmol), cesium fluoride (96mg, 0.63mmol) and A1-9(78mg, 0.31mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (50 mg, 37%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.39 (s, 1H), 8.26 (s, 1H), 8.15 (s, 1H), 7.46 (s, 1H), 6.66 (s, 1H), 4.54 (s, 2H), 4.02 (m, 1H), 3.61-3.58 (m, 5H), 3.05 (m, 1H), 2.41 (s, 3H), 2.11 (s, 3H), 2.01-1.99 (m, 4H), 1.37 (d, J=6.8Hz, 3H); ESI-MS (m/z): 434.9[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000351
Embodiment 29
The present embodiment provides a kind of new antitumoral compounds A29, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000352
1) intermediate A 29-1's is synthetic:
A28-1(250mg, 0.76mmol) with 4-hydroxy piperidine (232mg, 2.3mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=1:1) a white solid (200mg, 75%).
3) intermediate A 29-2's is synthetic:
By A29-1(200mg, 0.57mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained white solid (100mg, 71%) and be directly used in next step with reversed-phase preparative chromatography.
3) product A 29 is synthetic:
A29-1 (77mg, 0.31mmol), cesium fluoride (96mg, 0.63mmol) and A1-9(78mg, 0.31mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil, place in air and within 24 hours, change yellow solid into, purifying obtains white solid (10mg, 6.7%) again.Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.89 (s, 1H), 8.47 (s, 1H), 8.34 (s, 1H), 8.01 (s, 1H), 7.44 (s, 1H), 4.52-4.48 (m, 2H), 4.42-4.38 (m, 1H), 4.02-4.00 (m, 2H), 3.55-3.50 (m, 1H), 3.12-3.10 (m, 1H), 2.37 (s, 3H), 2.23 (s, 3H), 1.97 (m, 2H), 1.62 (m, 2H), 1.39 (d, J=6.8Hz, 3H); ESI-MS (m/z): 478.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000361
Embodiment 30
The present embodiment provides a kind of new antitumoral compounds A30, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000362
1) intermediate A 30-1's is synthetic:
4-tertbutyloxycarbonyl piperidone (1g, 5.0mmol) is dissolved in anhydrous tetrahydro furan, and at nitrogen protection borehole cooling, to zero degree, sodium hydride (80%, 332mg, 11mmol) is added drop-wise in above-mentioned solution at this temperature; After 30 minutes, methyl iodide (1.56g, 11mmol) adds under zero degree, and reaction at room temperature continues to stir 3 hours.With saturated aqueous ammonium chloride solution cancellation, add ethyl acetate (20mL) extraction, organic phase is revolved desolventizing after filtering with anhydrous sodium sulfate drying, solute through column chromatography refining (moving phase is sherwood oil: ethyl acetate=20:1) a colourless oil liquid (600mg, 53%).
2) intermediate A 30-2's is synthetic:
By A30-1(7g, 31mmol) in molten 50 milliliters of DMFs, then add DMF dimethylacetal (7.4g, 62mmol), finish 80 ℃ of reactions 12 hours.Be cooled to room temperature, revolve and steam to such an extent that an orange crude product is directly cast single step reaction.Under normal temperature, by sulfuric acid half methyl-thiourea (4.3g, 15.4mmol) and sodium ethylate (2.1g, 31mmol) be dissolved in 80 milliliters of ethanol, stir after half an hour, 20 milliliters of ethanolic solns that add the synthetic orange crude product of step, backflow 12h, is cooled to room temperature, underpressure distillation, enriched material dilute with water, ethyl acetate extraction, organic phase is washed with saturated common salt, after anhydrous sodium sulfate drying filters, evaporated under reduced pressure, through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:5) a colorless oil (6g, 62%).
3) intermediate A 30-3's is synthetic:
By A30-2(200mg, 0.64mmol) be dissolved in 3M ethyl acetate solution (5mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (110mg, 82.5%) and be directly used in next step with reversed-phase preparative chromatography.
4) product A 30 is synthetic:
A30-3 (106mg, 0.51mmol), cesium fluoride (156mg, 1.02mmol) and A1-9(129mg, 0.51mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (62mg, 29%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.37 (s, 1H), 8.30 (s, 1H), 8.24 (s, 1H), 7.45 (s, 1H), 6.68 (s, 1H), 4.62 (s, 2H), 3.68 (s, 2H), 2.57 (s, 3H), 2.39 (s, 3H), 2.19 (s, 3H), 1.34 (s, 6H); ESI-MS (m/z): 425.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000371
Embodiment 31
The present embodiment provides a kind of new antitumoral compounds A31, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000372
1) intermediate A 31-1's is synthetic:
By A30-2(5g, 16mmol) after being dissolved in 100 milliliters of methylene dichloride of 0 ℃, slowly add while stirring metachloroperbenzoic acid (85%, 5.6g, 32mmol), after stirring at normal temperature 12 hours, the saturated aqueous solution (20mL) that adds sodium bicarbonate (20mL) and Sulfothiorine, stirring at normal temperature 30 minutes, organic phase underpressure distillation is concentrated, through column chromatography refining (moving phase is sherwood oil: ethyl acetate=3:1) a white solid (2.5g, 46%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.62 (s, 1H), 4.74 (s, 2H), 3.56 (s, 2H), 3.41 (s, 3H), 1.50 (s, 9H), 1.40 (s, 6H).
2) intermediate A 31-2's is synthetic:
A31-1(400mg, 1.2mmol) and cyclopropylamine (342mg, 5mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), heat 90 ℃, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (300mg, 79%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.24 (s, 1H), 4.47 (s, 2H), 3.44 (s, 2H), 2.74 (m, 1H), 1.49 (s, 9H), 1.25 (s, 6H), 0.79 (m, 2H), 0.52 (m, 2H).
3) intermediate A 31-3's is synthetic:
By A31-2(300mg, 0.94mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (200mg, 97%) and be directly used in next step with reversed-phase preparative chromatography.Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 7.99 (s, 1H), 5.17 (s, 1H), 3.86 (s, 2H), 2.89 (s, 2H), 2.73 (m, 1H), 1.25 (s, 6H), 0.75 (m, 2H), 0.53 (m, 2H).
4) product A 31 is synthetic:
A31-3 (111mg, 0.51mmol), cesium fluoride (156mg, 1.02mmol) and A1-9(129mg, 0.51mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (60mg, 27%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.36 (s, 1H), 8.24 (s, 1H), 8.19 (s, 1H), 7.44 (s, 1H), 6.64 (s, 1H), 5.38 (s, 1H), 4.53 (s, 2H), 3.65 (s, 2H), 2.68 (m, 1H), 2.38 (s, 3H), 2.19 (s, 3H), 1.30 (s, 6H), 0.81 (m, 2H), 0.55 (m, 2H); ESI-MS (m/z): 434.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000381
Embodiment 32
The present embodiment provides a kind of new antitumoral compounds A32, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000382
1) intermediate A 32-1's is synthetic:
A31-1(150mg, 0.44mmol) and Pyrrolidine (156mg, 2.2mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), heat 90 ℃, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (110mg, 75%).
2) intermediate A 32-2's is synthetic:
By A32-1(110mg, 0.33mmol) be dissolved in 3M ethyl acetate solution (5mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained white solid (60mg, 78%) and be directly used in next step with reversed-phase preparative chromatography.
3) product A 32 is synthetic:
A32-2 (47.6mg, 0.21mmol), cesium fluoride (64mg, 0.42mmol) and A1-9(54mg, 0.21mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (30mg, 32%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.36 (s, 1H), 8.23 (s, 1H), 8.10 (s, 1H), 7.43 (s, 1H), 6.63 (s, 1H), 4.50 (s, 2H), 3.66 (br s, 2H), 3.58 (br, 4H), 2.38 (s, 3H), 2.19 (s, 3H), 1.98 (m, 4H), 1.31 (s, 6H); ESI-MS (m/z): 448.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000391
Embodiment 33
The present embodiment provides a kind of new antitumoral compounds A33, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000392
1) intermediate A 33-1's is synthetic:
A31-1(400mg, 1.2mmol) He 2,6-lupetazin (399mg, 3.6mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), heat 90 ℃, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=25:1) a white solid (240mg, 53%).
2) intermediate A 33-2's is synthetic:
By A33-1(240mg, 0.64mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (130mg, 74%) and be directly used in next step with reversed-phase preparative chromatography.
3) product A 33 is synthetic:
A33-2 (130mg, 0.47mmol), cesium fluoride (156mg, 1.02mmol) and A1-9(129mg, 0.51 mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:25) a yellow solid (65mg, 28%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.36 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.44 (s, 1H), 6.64 (s, 1H), 4.80-4.77 (m, 2H), 4.53 (br, 2H), 3.66 (s, 2H), 3.14 (br, 2H), 2.89 (m, 2H), 2.38 (s, 3H), 2.19 (s, 3H), 1.47 (d, J=5.2Hz, 6H), 1.31 (s, 6H); ESI-MS (m/z): 491.8[M+1] +.
The solid spectrum analysis of gained is
Embodiment 34
The present embodiment provides a kind of new antitumoral compounds A34, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000402
1) intermediate A 34-1's is synthetic:
A31-1(400mg, 1.2mmol) with 4-hydroxy piperidine (360mg, 3.6mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), heat 90 ℃, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=25:1) a white solid (200mg, 46%).
2) intermediate A 34-2's is synthetic:
By A34-1(200mg, 0.55mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (120mg, 83%) and be directly used in next step with reversed-phase preparative chromatography.Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 7.97 (s, 1H), 4.45-4.42 (m, 2H), 3.92 (s, 1H), 3.85 (s, 2H), 3.23 (t, J=6.8Hz, 2H), 2.90 (s, 2H), 1.95-1.93 (m, 2H), 1.51-1.49 (m, 2H), 1.26 (s, 6H).
3) product A 34 is synthetic:
A34-2 (120mg, 0.46mmol), cesium fluoride (156mg, 1.02mmol) and A1-9(129mg, 0.51mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:25) a colorless oil, place in air and within 24 hours, change yellow solid into, purifying obtains white solid (10mg, 4.4%) again.Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.99 (s, 1H), 8.46 (s, 1H), 8.34 (s, 1H), 8.09 (s, 1H), 7.44 (s, 1H), 4.51-4.48 (m, 2H), 4.07 (s, 2H), 4.01 (br s, 1H), 3.51 (t, J=6.4Hz, 2H), 2.37 (s, 3H), 2.23 (s, 3H), 1.99-1.97 (m, 2H), 1.59-1.57 (m, 2H), 1.35 (s, 6H); ESI-MS (m/z): 492.8[M+1] +.
The oily matter spectrum analysis of gained is
Figure BDA0000392128440000411
Embodiment 35
The present embodiment provides a kind of new antitumoral compounds A35, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000412
1) intermediate A 1-2's is synthetic:
4-tertbutyloxycarbonyl piperidone (2g, 10.1mmol) and DMF dimethylacetal (18g, 151.5mmol) are stirred, and 90 ℃ are reacted 12 hours.Be cooled to room temperature, join in ethyl acetate (150mL) and water (50mL), saturated aqueous common salt for organic phase (50mL) washes twice, and anhydrous sodium sulfate drying filters, and revolves and steams to such an extent that an orange crude product (3.10g) is directly cast single step reaction.
2) intermediate A 35-1's is synthetic:
Under normal temperature, by Guanidinium hydrochloride (1.92g, 20.1mmol) and sodium ethylate (1.37g, 20.1mmol) be dissolved in ethanol (20mL), stir after half an hour, add the synthetic intermediate A 1-2 (3.10g of step, 12.2mmol), backflow reaction overnight.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, evaporated under reduced pressure, through column chromatography refining (moving phase is ethyl acetate: sherwood oil=2:1) an orange (750mg, 25%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.05 (s, 1H), 4.95 (s, 2H), 4.44 (s, 2H), 3.69 (t, J=5.8Hz, 2H), 2.75 (t, J=5.4Hz, 2H), 1.49 (s, 9H).
3) intermediate A 35-2's is synthetic:
By A35-1 (750mg, 3.0mmol) be dissolved in after the ethyl acetate of 3M, the saturated ethyl acetate solution (5mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins in saturated sodium bicarbonate aqueous solution in (5mL) and methylene dichloride (20mL), organic phase is washed with saturated common salt, anhydrous sodium sulfate drying is spin-dried for to obtain a white solid (350mg, 78%) after filtering.
4) product A 35 is synthetic:
A35-2 (50mg, 0.3mmol), cesium fluoride (125mg, 0.8mmol) and A1-9 (127mg, 0.5mmol) are dissolved in methyl-sulphoxide (1mL) respectively under agitation condition, are heated to 120 ℃, react 36 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=50:1) a yellow solid (80mg, 66%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.35 (s, 1H), 8.23 (s, 2H), 8.10 (s, 1H), 7.43 (s, 1H), 6.65 (s, 1H), 4.94 (s, 2H), 4.56 (s, 2H), 3.90 (t, J=5.8Hz, 2H), 2.87 (t, J=5.8Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H); ESI-MS (m/z): 366.8[M+1] +.
The solid of gained is through resolving to
Figure BDA0000392128440000421
Embodiment 36
The present embodiment provides a kind of new antitumoral compounds A36, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000422
A6(40mg, 0.090mmol) room temperature is placed in air three days, and with preparing plate, (developping agent is sherwood oil to mixture: ethyl acetate=1:2) purifying obtains white solid (2mg, 5%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.89 (s, 1H), 8.46 (s, 1H), 8.34 (s, 1H), 8.02 (s, 1H), 7.44 (s, 1H), 4.50-4.46 (m, 2H), 4.32 (t, J=7.0Hz, 2H), 4.01 (br s, 2H), 3.53 (t, J=10.0Hz, 2H), 3.02 (t, J=6.4Hz, 2H), 2.37 (s, 3H), 2.23 (s, 3H), 2.00-1.97 (m, 2H), 1.57-1.50 (m, 2H); ESI-MS (m/z): 464.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000423
Embodiment 37
The present embodiment provides a kind of new antitumoral compounds A37, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000431
1) intermediate A 37-1's is synthetic:
2,5-bis-chloro-4-boric acid pyridine (671mg, 3.5mmol) and 5-methyl-2-bromopyridine (500mg, 2.9mmol) are joined in the mixed solution of 5 milliliters of dioxane and 2 ml waters, then add Pd (dppf) Cl 2(212mg, 0.29mmol) and three water potassiumphosphates (1.16g, 4.35mmol), nitrogen exchange three times for reaction system, reflux is spent the night.Reaction solution cool to room temperature, adds 10 ml waters to filter, and filtrate extracts three times with methylene dichloride (10mL), and organic phase is filtered with anhydrous sodium sulfate drying, and filtrate was spin-dried for post (sherwood oil: ethyl acetate=50:1) obtain white solid (100mg, 15%). 1H-NMR(400MHz,CDCl 3):δ8.59(s,1H),8.47(s,1H),7.69-7.63(m,3H),2.44(s,3H)。
2) product A 37 is synthetic:
Respectively by A37-1 (30mg, 0.13mmol), A3-2(24mg, 0.13mmol) and C sf(38mg, 0.25mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 24h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is methylene dichloride to solute: methyl alcohol=50:1), obtain a yellow solid (20mg, 39%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.54 (s, 1H), 8.25 (s, 1H), 8.18 (s, 1H), 7.64-7.59 (m, 2H), 6.96 (s, 1H), 5.82 (br s, 1H), 4.58 (s, 2H), 3.92 (t, J=5.6Hz, 2H), 2.88 (t, J=5.6Hz, 2H), 2.77 (br s, 1H), 2.42 (s, 3H), 0.81 (s, 2H), 0.54 (s, 2H); ESI-MS (m/z): 392.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000432
Embodiment 38
The present embodiment provides a kind of new antitumoral compounds A38, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000433
1) intermediate A 38-1's is synthetic
In the three-necked bottle of a 25mL, add respectively the bromo-3-picoline of 2-(500mg, 2.82mmol), A1-8 (700mg, 3.64mmol), K 3pO 4.3H 2o (1.50g, 5.64mmol), Pd (dppf) Cl 2(103mg, 0.140mmol) and Isosorbide-5-Nitrae-dioxane/water (7:1,10mL), with after nitrogen replacement three times, be heated to 100 ℃, reaction 16h, be chilled to room temperature, filter, filtrate is spin-dried for, and with column chromatography, refining (moving phase is sherwood oil: ethyl acetate=20:1), obtain a white solid (40mg, 6%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.55 (d, J=4.4Hz, 1H), 8.48 (s, 1H), 7.65 (d, J=7.6Hz, 1H), 7.34 (s, 1H), 7.33-7.31 (m, 1H), 2.20 (s, 3H).
2) product A 38 is synthetic
Respectively by A38-1 (40mg, 0.17mmol), A3-2(50mg, 0.26mmol) and C sf(64mg, 0.43mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (2mg, 3%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.53 (d, J=4.4Hz, 1H), 8.25 (s, 1H), 8.17 (s, 1H), 7.62 (d, J=7.6Hz, 1H), 7.29-7.28 (m, 1H), 5.28 (s, 1H), 4.56 (s, 2H), 3.99-3.83 (m, 2H), 2.89 (t, J=11.2Hz, 2H), 2.83-2.73 (m, 1H), 2.21 (s, 3H), 0.85-0.78 (m, 2H), 0.59-0.48 (m, 2H); ESI-MS (m/z): 392.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000441
Embodiment 39
The present embodiment provides a kind of new antitumoral compounds A39, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000442
1) intermediate A 39-1's is synthetic:
By 2, the chloro-4-boric acid of 5-bis-pyridine (550mg, 2.9mmol) with 2-bromoquinoline (500mg, 2.3mmol) join in the mixed solution of 2.4 milliliters of 2N solution of potassium carbonate, 5 milliliters of ethanol and 5 milliliters of toluene, then add tetra-triphenylphosphine palladium (275mg, 0.24mmol), nitrogen exchange three times for reaction system, tube sealing is heated to 105 ℃.Reaction solution cool to room temperature, adds 10 ml waters to filter, and filtrate extracts three times with methylene dichloride (10mL), and organic phase is filtered with anhydrous sodium sulfate drying, and filtrate was spin-dried for post (sherwood oil: ethyl acetate=25:1) obtain white solid (210mg, 32%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3): δ 8.52 (s, 1H), 8.31 (d, J=8.4Hz, 1H), 8.18 (d, J=8.8Hz, 1H), 7.92 (d, J=8.0Hz, H), 7.81-7.79 (m, 2H), 7.76 (s, 1H), 7.66 (t, J=7.2Hz, 1H).
2) product A 39 is synthetic:
Respectively by A39-1 (40mg, 0.15mmol), A3-2(37mg, 0.15mmol) and C sf(44mg, 0.29 mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 24h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is methylene dichloride to solute: methyl alcohol=50:1), obtain a light yellow solid (20mg, 32%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.23 (s, 1H), 8.19 (d, J=8.4Hz, 1H), 8.14-8.12 (m, 2H), 7.83 (d, J=8.4Hz, 1H), 7.71-7.68 (m, 2H), 7.55 (d, J=7.2Hz, 1H), 6.97 (s, 1H), 5.39 (br s, 1H), 4.54 (s, 2H), 3.89 (t, J=5.6Hz, 2H), 2.83 (t, J=5.6Hz, 2H), 2.69 (br s, 1H), 0.76-0.74 (m, 2H), 0.46 (s, 2H); ESI-MS (m/z): 428.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000451
Embodiment 40
The present embodiment provides a kind of new antitumoral compounds A40, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000452
1) intermediate A 40-1's is synthetic
In the three-necked bottle of a 25mL, add respectively 2-bromopyridine (100mg, 0.63mmol), A1-8 (240mg, 1.25mmol), K 2cO 3(175mg, 1.27mmol), Pd (dppf) Cl 2(50mg, 0.068mmol) and glycol dimethyl ether/water (7:1,5mL), with after nitrogen replacement three times, be heated to 90 ℃, reaction 4h, is chilled to room temperature, filters, filtrate is spin-dried for, with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=2:1), obtain a white solid (45mg, 32%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.77 (d, J=4.4Hz, 1H), 8.48 (s, 1H), 7.86-7.82 (m, 1H), 7.76 (d, J=8.0Hz, 1H), 7.66 (s, 1H), 7.42-7.39 (m, 1H).
2) product A 40 is synthetic
Respectively by A40-1 (45mg, 0.20mmol), A3-2 (60mg, 0.32mmol) and C sf(100mg, 0.67mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (8mg, 14%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.75 (d, J=4.8Hz, 1H), 8.27 (s, 1H), 8.20 (s, 1H), 7.83-7.79 (m, 1H), 7.72 (d, J=8.0Hz, 1H), 7.38-7.35 (m, 1H), 6.97 (s, 1H), 5.24 (s, 1H), 4.59 (s, 2H), 3.94 (t, J=11.6Hz, 2H), 2.89 (t, J=11.6Hz, 2H), 2.80-2.74 (m, 1H), 0.85-0.80 (m, 2H), 0.55-0.52 (m, 2H); ESI-MS (m/z): 378.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000461
Embodiment 41
The present embodiment provides a kind of new antitumoral compounds A41, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000462
1) intermediate A 41-1's is synthetic
In the three-necked bottle of a 25mL, add respectively the bromo-5-5-flumethiazine of 2-(100mg, 0.44mmol), A1-8 (150mg, 0.78mmol), K 3pO 4.3H 2o (230mg, 0.86mmol), Pd (dppf) Cl 2(32mg, 0.044mmol) and tetrahydrofuran (THF)/water (7:1,5mL), with after nitrogen replacement three times, be heated to 60 ℃, reaction 16h, is chilled to room temperature, filters, filtrate is spin-dried for, and with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=3:2), obtain a white solid (43mg, 33%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 9.03 (s, 1H), 8.52 (s, 1H), 8.09 (d, J=8.0Hz, 1H), 7.91 (d, J=8.0Hz, 1H), 7.67 (s, 1H).
2) product A 41 synthetic
Respectively by A41-1 (43mg, 0.15mmol), A3-2(40mg, 0.21mmol) and C sf(70mg, 0.47mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (11mg, 17%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 9.04 (s, 1H), 8.75-8.71 (m, 1H), 8.65 (d, J=2.0Hz, 1H), 8.30 (s, 1H), 8.21 (s, 1H), 6.96 (s, 1H), 5.48 (br s, 1H), 4.60 (s, 2H), 3.95 (t, J=12.0Hz, 2H), 2.92 (t, J=12.0Hz, 2H), 2.78-2.77 (m, 1H), 0.85-0.81 (m, 2H), 0.56-0.53 (m, 2H); ESI-MS (m/z): 446.8[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000471
Embodiment 42
The present embodiment provides a kind of new antitumoral compounds A42, and the synthetic method of this compound is as follows:
1) intermediate A 42-1's is synthetic:
By 2, the chloro-4-boric acid of 5-bis-pyridine (290mg, 1.5mmol) with 2-bromo pyrimi piperidine (200mg, 1.26mmol) join in the mixed solution of 1.3 milliliters of 2N solution of potassium carbonate, 3 milliliters of ethanol and 3 milliliters of toluene, then add tetra-triphenylphosphine palladium (146mg, 0.13mmol), nitrogen exchange three times for reaction system, tube sealing is heated to 115 ℃.Reaction solution cool to room temperature, adds 5 ml waters to filter, and filtrate extracts three times with methylene dichloride (10mL), and organic phase is filtered with anhydrous sodium sulfate drying, and filtrate was spin-dried for post (sherwood oil: ethyl acetate=25:1) obtain white solid (60mg, 21%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3): δ 8.86 (d, J=4.8Hz, 2H), 8.45 (s, 1H), 7.73 (s, 1H), 7.33 (t, J=4.8Hz, 1H).
2) product A 42 is synthetic:
Respectively by A42-1 (20mg, 0.09mmol), A3-2(17mg, 0.09mmol) and C sf(27mg, 0.18mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 24h, is chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is methylene dichloride to solute: methyl alcohol=100:1), obtain a light yellow solid (7mg, 20%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.97 (d, J=4.8Hz, 2H), 8.31 (s, 1H), 8.20 (s, 1H), 7.37 (t, J=4.8Hz, 1H), 7.08 (s, 1H), 5.29 (br s, 1H), 4.59 (s, 2H), 3.94 (t, J=6.0Hz, 2H), 2.90 (t, J=5.6Hz, 2H), 2.77 (br s, 1H), 0.84-0.80 (m, 2H), 0.54 (s, 2H); ESI-MS (m/z): 380.1[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000473
Embodiment 43
The present embodiment provides a kind of new antitumoral compounds A43, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000481
1) intermediate A 43-1's is synthetic
In the tube sealing of a 25mL, add respectively 2-chloropyrazine (100mg, 0.87mmol), A1-8 (340mg, 1.77mmol), Na 2cO 3(185mg, 1.74mmol), Pd (PPh 3) 4(170mg, 0.15mmol) and Isosorbide-5-Nitrae-dioxane/water (7:1,5mL), with nitrogen, blow 10min, be heated to 130 ℃, reaction 16h, be chilled to room temperature, filter, filtrate is spin-dried for, and with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=3:2), obtain a white solid (35mg, 18%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 9.09 (s, 1H), 8.78-8.75 (m, 1H), 8.70 (d, J=2.4Hz, 1H), 8.54 (s, 1H), 7.69 (s, 1H).
2) product A 43 is synthetic
Respectively by A43-1 (35mg, 0.15mmol), A3-2(40mg, 0.21mmol) and C sf(70mg, 0.47mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (10mg, 17%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 9.02 (s, 1H), 8.30 (s, 1H), 8.22 (s, 1H), 8.05 (d, J=8.0Hz, 1H), 7.88 (d, J=8.0Hz, 1H), 6.98 (s, 1H), 5.88 (br s, 1H), 4.62 (s, 2H), 3.95 (t, J=11.2Hz, 2H), 296 (t, J=11.2Hz, 2H), 2.83-2.77 (m, 1H), 0.87-0.83 (m, 2H), 0.60-0.56 (m, 2H); ESI-MS (m/z): 379.9[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000482
Embodiment 44
The present embodiment provides a kind of new antitumoral compounds A44, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000491
1) intermediate A 44-1's is synthetic
After glycol dibromide (40mg, 0.21mmol) being added in the tetrahydrofuran (THF) suspension of zinc, be heated to 50 ℃, after 5min, add successively TMSCl(20mg, 0.18mmol) and the tetrahydrofuran solution (1mL) of 2-bromo thiazole, 50 ℃ of reaction 1h.The tetrahydrofuran solution of prepared 2-bromo thiazole zincon is injected to the chloro-4-iodine pyridine of 2,5-bis-(300mg, 1.09mmol) and Pd (PPh 3) 4in the tetrahydrofuran solution of (40mg, 0.035mmol) (10mL), be heated to reflux, after reaction 12h, be chilled to room temperature, filter, filtrate is spin-dried for, with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=3:2), obtain a white solid (60mg, 24%).Its chemical shift is as follows: 1h-NMR (300MHz, CDCl 3) δ 8.53 (s, 1H), 8.51 (s, 1H), 8.08-8.07 (m, 1H), 7.68-7.67 (m, 1H).
2) product A 44 is synthetic
Respectively by A44-1 (50mg, 0.22mmol), A3-2(50mg, 0.26mmol) and C sf(130mg, 0.85mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (8mg, 10%).Its chemical shift is as follows: 1h-NMR (300MHz, CDCl 3) δ 8.31 (s, 1H), 8.24 (s, 1H), 8.02 (d, J=3.0Hz, 1H), 7.62 (s, 1H), 7.61 (d, J=3Hz, 1H), 5.70 (br s, 1H), 4.63 (s, 2H), 3.98 (t, J=11.2Hz, 2H), 2.99-2.93 (m, 2H), 2.83-2.75 (m, 1H), 0.87-0.81 (m, 2H), 0.61-0.50 (m, 2H).
The solid spectrum analysis of gained is
Figure BDA0000392128440000492
Embodiment 45
The present embodiment provides a kind of new antitumoral compounds A45, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000493
After being dissolved in to Isosorbide-5-Nitrae-dioxane (1mL), A35 (50mg, 0.1mmol) adds N, N-diisopropylethylamine (53mg, 0.4mmol) adds Vinyl chloroformate (18mg under agitation condition, 0.2mmol), be heated to 100 ℃, reaction overnight.Be cooled to room temperature, add methylene dichloride (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute, through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:1 is to 3:1), obtains a yellow solid (20mg, 33%).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.40 (s, 1H), 8.35 (s, 1H), 8.24 (s, 1H), 7.60 (s, 1H), 7.43 (s, 1H), 6.68 (s, 1H), 4.66 (s, 2H), 4.28 (m, 2H), 3.93 (s, 2H), 3.02 (s, 2H), 2.38 (s, 3H), 2.17 (s, 3H), 1.32 (t, J=7.0Hz, 3H).
The solid spectrum analysis of gained is
Figure BDA0000392128440000501
Embodiment 46
The present embodiment provides a kind of new antitumoral compounds A46, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000502
After A35 (50mg, 0.1mmol) is dissolved in to anhydrous tetrahydro furan (1mL) with sodium hydride (33mg, 1.4mmol), stir 30 minutes, under agitation condition, add ethyl isocyanate (48.5mg, 0.7mmol).At normal temperatures after reaction overnight, add methylene dichloride (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute obtains a yellow solid (15mg, 25%) through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:1 is to 3:1).Its chemical shift is as follows: 1h-NMR (400MHz, CDCl 3) δ 8.92 (s, 1H), 8.36 (s, 1H), 8.26 (s, 1H), 8.25 (s, 1H), 7.45 (s, 1H), 7.30 (s, 1H), 6.69 (s, 1H), 4.65 (s, 2H), 3.93 (s, 2H), 3.41 (t, J=6.4Hz, 2H), 2.98 (d, J=2.6Hz, 2H), 2.39 (s, 3H), 2.18 (s, 3H), 1.24 (t, J=7.0Hz, 3H).
The solid spectrum analysis of gained is
Figure BDA0000392128440000503
Embodiment 47
The present embodiment provides a kind of new antitumoral compounds A47, and the synthetic method of this compound is as follows:
After A35 (50mg, 0.1mmol) is dissolved in to anhydrous tetrahydro furan (1mL) with sodium hydride (8mg, 0.7mmol), stir 30 minutes, under agitation condition, add n-Isopropyl isocyanate (58.10mg, 0.3mmol).At normal temperatures after reaction overnight, add methylene dichloride (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute obtains a yellow solid (11mg, 17%) through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:1 is to 3:1).Its chemical shift is as follows: 1h-NMR (300MHz, CDCl 3) δ 8.87 (s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 7.44 (s, 1H), 7.39 (s, 1H), 6.68 (s, 1H), 4.64 (s, 2H), 4.08 (m, 1H), 3.93 (t, J=5.7Hz, 2H), 2.96 (t, J=5.4Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.26 (d, J=3Hz, 6H).
The solid spectrum analysis of gained is
Embodiment 48
The present embodiment provides a kind of new antitumoral compounds A48, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000512
1) intermediate A 48-1's is synthetic
In the three-necked bottle of a 25mL, add respectively 3-bromopyridine (100mg, 0.63mmol), A1-8 (240mg, 1.25mmol), Na 2cO 3(135mg, 1.27mmol), Pd (dppf) Cl 2(45mg, 0.061mmol) and glycol dimethyl ether/water (7:1,5mL), with after nitrogen replacement three times, be heated to 100 ℃, reaction 16h, is chilled to room temperature, filters, filtrate is spin-dried for, with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=3:2), obtain a white solid (30mg, 21%). 1H-NMR(300MHz,CDCl 3)δ8.72(s,2H),8.50(s,1H),7.84-7.81(m,1H),7.46-7.42(m,1H),7.35(s,1H)。
2) product A 48 is synthetic
Respectively by A48-1 (30mg, 0.13mmol), A3-2(40mg, 0.21mmol) and C sf(80mg, 0.53mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (10mg, 20%).Its chemical shift is as follows: 1h-NMR (300MHz, CDCl 3) δ 8.70 (s, 1H), 8.27 (s, 1H), 8.22 (s, 1H), 7.83 (d, J=8.1Hz, 1H), 7.43-7.39 (m, 1H), 6.64 (s, 1H), 5.74 (br s, 1H), 4.59 (s, 2H), 3.93 (t, J=11.2Hz, 2H), 2.94 (t, J=11.7Hz, 2H), 2.82-2.76 (m, 1H), 0.87-0.81 (m, 2H), 0.59-0.54 (m, 2H); ESI-MS (m/z): 378.9[M+1] +.
The solid spectrum analysis of gained is
Figure BDA0000392128440000521
Embodiment 49
The present embodiment provides a kind of new antitumoral compounds A49, and the synthetic method of this compound is as follows:
Figure BDA0000392128440000522
After being dissolved in to Isosorbide-5-Nitrae-dioxane (1mL), A35 (50mg, 0.1mmol) adds N, N-diisopropylethylamine (88.11mg, 0.7mmol) adds trimethyl-acetyl chloride (49.43mg under agitation condition, 0.4mmol), be heated to 100 ℃, reaction overnight.Be cooled to room temperature, add methylene dichloride (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute obtains a yellow solid (20mg, 32%) through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:1 is to 3:1).Its chemical shift is as follows: 1h-NMR (300MHz, CDCl 3) δ 8.40 (s, 1H), 8.35 (s, 1H), 8.24 (s, 1H), 8.06 (s, 1H), 7.43 (s, 1H), 6.68 (s, 1H), 4.67 (s, 2H), 3.93 (t, J=5.7Hz, 2H), 3.04 (t, J=5.8Hz, 2H), 2.38 (s, 3H), 2.17 (s, 3H), 1.33 (s, 9H).
The solid spectrum analysis of gained is
Figure BDA0000392128440000523
Embodiment 50
The present embodiment carries out biological NIH3T3-GRE-Luc luciferase reporter gene test experience to the compound of embodiment 1-49 gained, the barrier effect of checking gained compound to hedgehog path Hedgehog (Hh).
NIH3T3 cell be the DMEM that contains 10%FBS (Hyclone) (11965, cultivate in Gibico).GRE-firefly luciferin plasmid is to implant in MCS and obtain via the cell transcription factor GLI-1 response element that amplifies octuple.Mono-clonal is through restructuring Su Nike hedgehog path albumen and small molecules agonist SAG checking.The selected clone who is verified is for detection of hedgehog path signal.The NIH3T3 cell of expressing GRE-Lampyridea element is to maintain in complete nutrient solution.When needs are done analyzing and testing, cell is added in 96 orifice plates, and final every hole is containing cell approximately 15,000.96 orifice plates are being cultivated 48 hours.Detected compound is by DMSO and detect damping fluid by serial dilution.10nMSAG is as hedgehog path agonist.The analysis buffer that 100 microlitres include test compound and agonist subsequently carefully joins and contains in cell in 96 orifice plates, and cultivates 48 hours at 37 degrees Celsius.After cultivating 48 hours, 40 microlitre Photinus pyralis LUCs are added in each hole.96 orifice plates are jog 5 minutes at room temperature.Luminous signal is by reading plate device record.The activity of compound is calculated by its blocking-up to luminous signal.The present embodiment according to above-mentioned NIH3T3-GRE-Luc luciferase reporter gene test experience, choosing small molecules SMO antagonist GDC-0449 is control drug, biological activity to the compd A 1-A49 in embodiment is measured, experimental result is as shown in the table: experimental result shows, the IC50 of some of them compound is better than control drug.
Figure BDA0000392128440000531
Figure BDA0000392128440000541
Figure BDA0000392128440000551
Figure BDA0000392128440000571
Figure BDA0000392128440000581
As seen from the above-described embodiment, the antineoplastic compound of the embodiment of the present invention, by blocking-up transmembrane protein acceptor SMO, can be blocked hedgehog path Hedgehog, thereby suppress cellular abnormality, increases, and blocking-up tumour cell shifts regeneration.
The present invention still has numerous embodiments, and all employing equivalents or equivalent transformation and all technical schemes of forming, within all dropping on protection scope of the present invention.

Claims (11)

1. pyrimidine skeleton has a new antitumoral compounds for hedgehog path antagonistic activity, comprises this compound and pharmacy acceptable salt thereof, various isotropic substance, various isomer or various crystalline structure, has the structure shown in general formula I:
Figure FDA0000392128430000011
Wherein, X is five yuan or hexa-atomic aromatic nucleus, fragrant heterocycle, heterocycle, and the substitutive derivative of described ring, n is 0,1,2,3,4,5 or 6, R1, R2, R3, R4, R5, R6 is independently selected from respectively: hydrogen atom, halogen, alkane is for halogen, cyano group, alkane is for cyano group, trifluoromethyl, alkyl, thiazolinyl, alkynyl, amino, O, hydroxyl, S, sulfydryl, alkoxyl group, fat base, amide group, urea groups, oxo urea groups, thioureido, sulfuryl, sulfoxide group, sulfahydantoin, azido-, alkane is for thiazolinyl, alkane is for alkynyl, alkane is for amino, alkane is for hydroxyl, alkane is for fat base, alkane is for sulfuryl, alkane is for sulfoxide group, alkane is for sulfahydantoin, alkane is for azido-, cyclic alkyl, ring-type thiazolinyl, 3-12 heterocycle, aromatic nucleus or 5-12 virtue heterocycle or the substituting group of rolling into a ball containing heteroatom functional.
2. a kind of pyrimidine skeleton according to claim 1 has the new antitumoral compounds of hedgehog path antagonistic activity, this compound and pharmacy acceptable salt thereof, various isotropic substance, various isomer or various crystalline structure, comprise general formula I I or general formula III structure:
Figure FDA0000392128430000012
Wherein: A is nitrogen-atoms or C-R7, n is 0,1,2,3,4,5 or 6, R1, R2, R3, R4, R5, R6, R7 is independently selected from respectively: hydrogen atom, halogen, alkane is for halogen, cyano group, alkane is for cyano group, trifluoromethyl, alkyl, thiazolinyl, alkynyl, amino, O, hydroxyl, S, sulfydryl, alkoxyl group, fat base, amide group, urea groups, oxo urea groups, thioureido, sulfuryl, sulfoxide group, sulfahydantoin, azido-, alkane is for thiazolinyl, alkane is for alkynyl, alkane is for amino, alkane is for hydroxyl, alkane is for fat base, alkane is for sulfuryl, alkane is for sulfoxide group, alkane is for sulfahydantoin, alkane is for azido-, cyclic alkyl, ring-type thiazolinyl, 3-12 heterocycle, aromatic nucleus or 5-12 virtue heterocycle or the substituting group of rolling into a ball containing heteroatom functional.
3. a kind of pyrimidine skeleton according to claim 2 has the new antitumoral compounds of hedgehog path antagonistic activity, it is characterized in that:
Described alkyl is alkyl or the substituted hydrocarbon radical of saturated straight chain, side chain, ring-type, double-ring or the Spirocyclic of 1-10 carbon atom composition;
Described thiazolinyl is alkyl or the substituted hydrocarbon radical of the straight chain that contains at least one carbon-carbon double bond, side chain, ring-type, double-ring or the Spirocyclic of 1-10 carbon atom composition;
Described alkynyl is alkyl or the substituted hydrocarbon radical of the straight chain, side chain, ring-type, double-ring or the Spirocyclic that contain at least one carbon carbon triple bond of 1-10 carbon atom composition;
The substituting group of the monocycle that described fragrant cyclic group is aromaticity, many rings or heterocyclic substituent and substitutive derivative thereof, and the cyclic substituents derivative with saturated rings;
Described heterocyclic radical is monocycle, dicyclo, three ring or the volution substituting groups of the nonaromatic combination that comprises an atom in nitrogen, oxygen and sulphur or a plurality of atoms, and the cyclic substituents of their various oxidation state;
The described substituting group containing heteroatom functional group is the halogeno-group containing F, Cl, Br or I or the substituting group that comprises the one or more atoms in nitrogen, oxygen, sulphur and phosphorus, and their various oxidation state, and the quaternary ammonium salt of nitrogen.
4. a kind of pyrimidine skeleton according to claim 2 has the new antitumoral compounds of hedgehog path antagonistic activity, it is characterized in that: described R1, R2, R3, R4, R5, R6, R7 is independently selected from respectively: hydrogen atom, alkyl, thiazolinyl, alkynyl, fragrant cyclic group or heterocyclic radical that hydrogen atom is replaced by halogeno-group, cyano group, amino, hydroxyl, sulfydryl, alkoxyl group, ester group, sulfuryl, sulfoxide group, sulfahydantoin or azido-, and cyclic alkyl, ring-type thiazolinyl, 3-12 unit's heterocyclic radical or 5-12 membered aromatic heterocycle base; The alkyl that described hydrogen atom is replaced by halogeno-group is preferably trifluoromethyl.
5. according to a kind of pyrimidine skeleton described in claim 1-4 any one, there is the new antitumoral compounds of hedgehog path antagonistic activity, it is characterized in that: the structure of X is any one in lower array structure:
Figure FDA0000392128430000031
6. according to a kind of pyrimidine skeleton described in claim 1-5 any one, there is the new antitumoral compounds of hedgehog path antagonistic activity, it comprises following compounds, and pharmacy acceptable salt, various isotropic substance, various isomer or various crystalline structure:
Figure FDA0000392128430000041
Figure FDA0000392128430000051
7. a kind of pyrimidine skeleton according to claim 6 has the new antitumoral compounds of hedgehog path antagonistic activity, it is characterized in that: the methylamino in compound or substituted methylamine base replace with any one in following amine and analogue thereof:
8. according to a kind of pyrimidine skeleton described in claim 1-7 any one, have the new antitumoral compounds of hedgehog path antagonistic activity, it comprises following compound:
Figure FDA0000392128430000061
Figure FDA0000392128430000071
Figure FDA0000392128430000081
9. an antitumor medicine composition, comprises the combination that at least two kinds of compounds in new antitumoral compounds, its pharmacy acceptable salt, various isotropic substance, various isomer or the various crystalline structure that the pyrimidine skeleton with formula I structure described in claim 1-8 has hedgehog path antagonistic activity form.
10. a combined utilization composition for antitumor drug, this combined utilization composition be the pyrimidine skeleton described in claim 1-8 have the new antitumoral compounds of hedgehog path antagonistic activity and pharmaceutical composition thereof respectively with cis-platinum, taxol, camptothecine, Herceptin, imatinib mesylate, imatinib, Gefitinib, erlotinib, lapatinibditosylate in one or more combination carry out the composition that combined utilization obtains.
The application of the combined utilization composition of new antitumoral compounds, antitumor medicine composition or antitumor drug that pyrimidine skeleton described in 11. 1 kinds of claim 1-10 has a hedgehog path antagonistic activity in the medicine of preparation treatment tumour, described tumour comprises liver cancer, lung cancer, the rectum cancer, cervical cancer, cancer of pancreas, breast cancer, cancer of the stomach, oral carcinoma, the esophageal carcinoma, nasopharyngeal carcinoma, skin carcinoma, osteocarcinoma, the combination of one or more in kidney and leukemia.
CN201310463448.2A 2013-01-15 2013-10-08 A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist Active CN103694236B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201310463448.2A CN103694236B (en) 2013-01-15 2013-10-08 A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist
PCT/US2013/077305 WO2014113191A1 (en) 2013-01-15 2013-12-20 Hedgehog pathway signaling inhibitors and therapeutic applications thereof
US14/761,166 US9695178B2 (en) 2013-01-15 2013-12-20 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof
EP13871618.8A EP2945623B1 (en) 2013-01-15 2013-12-20 Hedgehog pathway signaling inhibitors and therapeutic applications thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201310014254 2013-01-15
CN2013100142544 2013-01-15
CN201310014254.4 2013-01-15
CN201310463448.2A CN103694236B (en) 2013-01-15 2013-10-08 A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist

Publications (2)

Publication Number Publication Date
CN103694236A true CN103694236A (en) 2014-04-02
CN103694236B CN103694236B (en) 2017-05-31

Family

ID=50079123

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310465383.5A Active CN103588771B (en) 2013-01-15 2013-10-08 There is the miazines antineoplastic compound of activity of hedgehog path antagonist
CN201310463448.2A Active CN103694236B (en) 2013-01-15 2013-10-08 A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310465383.5A Active CN103588771B (en) 2013-01-15 2013-10-08 There is the miazines antineoplastic compound of activity of hedgehog path antagonist

Country Status (1)

Country Link
CN (2) CN103588771B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790156A (en) * 2016-07-04 2019-05-21 苏州开拓药业股份有限公司 Chiral heterocycle compound with activity of hedgehog path antagonist and its preparation method and application
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CN107383009B (en) 2012-06-13 2020-06-09 因塞特控股公司 Substituted tricyclic compounds as FGFR inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG11201508328PA (en) 2013-04-19 2015-11-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
EP3124482B1 (en) 2014-03-24 2019-09-11 Guangdong Zhongsheng Pharmaceutical Co., Ltd Quinoline derivatives as smo inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
CN107438607B (en) 2015-02-20 2021-02-05 因赛特公司 Bicyclic heterocycles as FGFR inhibitors
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
AU2019262195B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022552324A (en) 2019-10-14 2022-12-15 インサイト・コーポレイション Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114423759B (en) * 2019-10-25 2023-10-20 江苏恒瑞医药股份有限公司 Fused heteroaryl derivatives, preparation method thereof and application thereof in medicines
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (en) 2019-12-04 2022-09-29 인사이트 코포레이션 Derivatives of FGFR inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
JP2024522189A (en) 2021-06-09 2024-06-11 インサイト・コーポレイション Tricyclic Heterocycles as FGFR Inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073772A1 (en) * 2007-12-06 2009-06-11 Smithkline Beecham Corporation Novel seh inhibitors and their use
WO2012052390A1 (en) * 2010-10-19 2012-04-26 Glaxo Group Limited N-2-(2-pyridinyl)-4-pyrimidinyl-beta-alanine derivatives as inhibitors of histone demethylase jmjd3

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543151T3 (en) * 2010-10-20 2015-08-17 Pfizer Inc 2-Pyridine derivatives as Smoothened receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073772A1 (en) * 2007-12-06 2009-06-11 Smithkline Beecham Corporation Novel seh inhibitors and their use
WO2012052390A1 (en) * 2010-10-19 2012-04-26 Glaxo Group Limited N-2-(2-pyridinyl)-4-pyrimidinyl-beta-alanine derivatives as inhibitors of histone demethylase jmjd3

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790156A (en) * 2016-07-04 2019-05-21 苏州开拓药业股份有限公司 Chiral heterocycle compound with activity of hedgehog path antagonist and its preparation method and application
CN113651816A (en) * 2016-07-04 2021-11-16 苏州开拓药业股份有限公司 Chiral heterocyclic compound with hedgehog pathway antagonist activity and preparation method and application thereof
CN113651816B (en) * 2016-07-04 2022-09-23 苏州开拓药业股份有限公司 Chiral heterocyclic compound with hedgehog pathway antagonist activity and preparation method and application thereof
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Also Published As

Publication number Publication date
CN103588771A (en) 2014-02-19
CN103588771B (en) 2016-01-27
CN103694236B (en) 2017-05-31

Similar Documents

Publication Publication Date Title
CN103694236A (en) Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity
ES2502941T3 (en) Method of preparation of dihydroindene amide compounds, pharmaceutical compositions containing said compounds and use as a protein kinase inhibitor
ES2368876T3 (en) DERIVATIVES OF 2-HETEROARILAMINOPIRIMIDINA AS KINASE INHIBITORS.
CN110573500B (en) N- (nitrogen heterocyclic aryl) lactam-1-formamide derivative and preparation method and application thereof
CN109311900A (en) Simple function intermediate for the degradation of ligand dependent target protein
CN101568529A (en) Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
CN101568530A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
CN108699055A (en) Heterocyclic compound as anticancer drug
EA023350B1 (en) Antimicrobial compounds, methods of making and using the same
CN106810536A (en) A kind of kinases inhibitor and preparation method thereof and medical usage
CN107698575A (en) The bifunctional molecule of novel B ET protein degradations ligand-mediated cereblon and its preparation and application
CN103923085B (en) Pyridine-heterocyclic compound with activity of hedgehog path antagonist and application thereof
KR20170106294A (en) Six-membered ring benzo deribatibes as dpp-4 inhibitor and use thereof
EP2560655A1 (en) Substituted pyrimidines
KR20200013702A (en) Ligand Compounds of α7 Nicotinic Acetylcholine Receptor and Their Applications
JP2021070688A (en) Pharmaceutical composition for prevention and/or treatment of hearing loss
CN114716448A (en) Heterocyclic compound for inhibiting activity of SHP2, preparation method and application thereof
CA2892927A1 (en) Use of maleimide derivatives for preventing and treating leukemia
JP7451765B2 (en) Pyridine acetamide derivatives as CDK inhibitors, their preparation methods and uses
CN115466289A (en) Compound with TYK2 inhibitory activity, pharmaceutical composition containing same, and application thereof
CN109422737A (en) Imidazolone androgen receptor antagonists, preparation method and use
CN104822658B (en) It is used as the fused tricyclic amides compound of a variety of kinase inhibitors
WO2023072301A1 (en) Pyrazolo[3,4-d]pyrimidin-3-one compound and medical use thereof
CN116249692B (en) Pyrazole compound as well as preparation method and application thereof
EP3592747A1 (en) Spirooxindole compounds as gsk3 inhibitors and process for preparation thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170426

Address after: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215123 Xinghu Street No. 218 BioBAY standing building C4-401

Applicant after: Suzhou pharmaceutical Limited by Share Ltd

Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215123 Xinghu Street No. 218 BioBAY A1 North Building 2 floor E36 room

Applicant before: SUZHOU YUNXUAN PHARMACEUTICAL CO., LTD.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant